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ABSTRACT 
Glioblastoma is a most aggressive brain tumor with a median overall survival of less than two 
years. The current treatment is surgery, chemotherapy, and radiotherapy. However, 
glioblastoma is difficult to treat and recurs some time after treatment. Several reports have 
shown that intratumoral heterogeneity is a hallmark of glioblastoma, and it is often said to be 
a factor that contributes to tumor progression and tumor relapse. 
Based on the single-cell gene expression profiling, glioblastoma is found to be composed of 
tumor cells with three different subtype signatures namely proneural, classical, and 
mesenchymal. These subtypes may transition between each other, which may be affected, 
and/or potentially controlled, by genetic and epigenetic modifications. Even 
microenvironmental events and communication between different subtype cells within the 
same tumor may play a role. Studies in this thesis focused on identifying regulators of 
subtype transitions and their involvement in cell-to-cell communication in individual 
glioblastomas. 
Study I used several analytical approaches including connectivity map analysis, 
overexpression screen, RNA-sequencing, and gene expression profiling. SOX2 was identified 
to have the capacity to transition mesenchymal gene expression subtype glioblastoma cells 
back to a non-mesenchymal signature. Subsequently, SFRP2 was identified as a SOX2 
antagonist able to induce a mesenchymal transition. In line with this, SFRP2 was found 
expressed at a higher level in mesenchymal as compared to proneural and classical TCGA 
glioblastoma samples. In vitro, SFRP2 decreased tumor sphere formation and cell 
proliferation, and increased cell invasion capacity and sensitivity towards apoptotic stimuli. 
Spatial gene expression analysis found SFRP2- correlated genes to be expressed in a higher 
level in vascularized areas in glioblastoma, as opposed to SOX2-correlated genes that were 
highly expressed in cellular tumor regions. Moreover, conditioned media from SFRP2 
transitioned cells induced more MRC1 (encodes CD206) expression in human monocytes in 
vitro. Collectively, these experiments identified SFPR2 as a SOX2 antagonist and inducer of 
mesenchymal transition in glioblastoma. 
In Study II PROX1 was found expressed at a lower level in glioblastoma as compared to low-
grade gliomas. Tumors with lower PROX1 correlated with a mesenchymal subtype and 
patients exhibited shorter survival. Suppression of PROX1 in glioblastoma cell lines with 
high PROX1 levels induced transition to a mesenchymal glioblastoma subtype signature. 
Conversely, overexpression of PROX1 transitioned cells to a non-mesenchymal subtype 
signature. In co-occurrence with these transitions, PROX1 functionally impacted on cell 
proliferation and levels of several cell cycle proteins. SOX2 was identified as an upstream 
signaling component of PROX1, and thus SOX2 and PROX1 levels decreased upon 
treatment with a CDK inhibitor. By co-immunoprecipitation experiments PROX1 was found 
to interact with THRAP3 in the nucleus. Depletion of THRAP3 increased PROX1 expression 
and protein stability. Based on previous reports on THRAP3, these findings suggest THRAP3 
to be involved in the transcriptional regulation of PROX1. These results underscore a 
functional role of PROX1 in glioblastoma development and with implications for survival 
outcome. 
In study III the well-known U-343 cell line system was used as a model system to study 
intratumoral heterogeneity and cell-to-cell communication. The four cell lines U-343 MG, U-
343 MGa, U-343 MGa 31L and U-343 MGa Cl2:6 are derived from the same glioblastoma, 
and display different phenotypes including marker expression, cells shape, and proliferation. 
Gene expression and DNA copy number analyses suggested their shared derivations from a 
common ancestor in a tumor evolutionary relationship. Temozolomide (TMZ) sensitivity of 
the individual cell lines was determined. In a cell culture composed of a mixture of all four 
cell lines, the one with the lowest sensitivity outlived the others during TMZ treatment, which 
modeled the appearance of drug resistance. Finally, co-culture and conditioned media 
experiments revealed complex interactions between the U-343 cell lines through signaling by 
cell-to-cell contact or secreted proteins. These findings provide a model for research on 
intratumoral heterogeneity, both with regard to appearance of drug resistance and to 
interclonal interactions. 
Collectively, these studies provide insights into the complexity of intratumoral heterogeneity, 
including subtype transitions during tumor progression and interclonal communication. 
Intratumoral heterogeneity is thus important to consider when designing new therapeutic 
strategies and may also in itself pose novel therapeutic targets.  
Keywords: glioblastoma, intratumoral heterogeneity, subtype transition, intercellular 
communication, U-343, SOX2, SFRP2, PROX1, THRAP3, TGFBI, NOTCH1, and 
ADAMTS1  
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1. GLIOBLASTOMA INTRODUCTION 
Glioblastoma, also known as glioblastoma multiforme, is the most aggressive glioma and 
accounts for 60% of all malignant primary brain tumors in adults. Glioblastoma has high 
morbidity and mortality, with a median overall survival of 12-18 months. It was reported that 
the incidence is higher in whites than Asians, and also more frequent in men than women by 
1.58 times [1]. There are several risk factors for developing glioblastoma, including 
environmental and patients’ intrinsic factors. Prior exposure to ionizing radiation is one 
established risk to develop glioblastoma [2]. 
Glioblastoma can be further classified as primary or secondary glioblastoma correlated with 
absence or presence of isocitrate dehydrogenases 1 and 2 (IDH1/2) mutations. Majority of 
glioblastomas are primary with wild-type IDH1/2, and arise from non-neoplastic cells, such 
as neural stem cells, glial progenitors or differentiated cells such as astrocytes [3]. Compared 
to secondary glioblastoma, primary glioblastoma has a worse prognosis even after intensive 
treatment. Patients with older age (>60 years) have an even shorter survival. Secondary 
glioblastoma often harbors IDH1 or IDH2 mutation, progresses from low-grade glioma and 
has a better prognosis [4, 5]. 
1.1 GLIOMAGENESIS 
Three theories have been proposed about the origin of primary glioblastoma, namely from the 
glioblastoma stem cells (GSCs), or via dedifferentiation from progenitor cells, or from 
astrocytes (Figure 1). 
 
Figure 1. Relation between neurogenesis and gliomagenesis. In the normal neurogenesis, neural stem cells (NSCs) give rise 
to neural- and glial-progenitors. Then neural progenitors differentiate into neurons, and glial progenitor cells differentiate into 
oligodendrocytes and astrocytes. However, during gliomagenesis, mutations that induce activation of oncogenic genes or loss 
of suppressive genes can happen in neural stem cells, progenitors or astrocytes, resulting in the generation of glioma stem 
cells (GSCs). GSCs can differentiate into non-mesenchymal and mesenchymal glioma cells and form tumor. On the other 
hand, some therapy stimuli can induce glioma cells dedifferentiate into GSCs. 
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Neural stem cells (NSCs) are reported as a source of glioblastoma initiation. NSCs are a 
small population of cells residing in neurogenic regions such as the subventricular zone 
(SVZ) and the hippocampus. NSCs give rise to neuroblasts and glial progenitor cells, which 
then develop to mature neurons, astrocytes or oligodendrocytes. GSCs share similar 
properties with NSCs, such as tumor sphere formation, and treatment resistance. In addition, 
glioblastomas are usually localized in the SVZ, making it reasonable that GSCs come from 
NSCs. Since many gene alterations exist in glioblastoma, it is hard to know if these 
alterations work singly or cooperatively during the transformation. Wang et al. have shown 
that Tp53 in-frame deletion mutation in neural stem cells, by using hGFAP-Cre/Tp53flox/flox 
mouse model, induced accumulation of oncogenic alterations in retinoblastoma (RB) and 
receptor tyrosine kinase (RTK) pathways, and promoted gliomagenesis [6]. Moreover, 
different mutations in the adult stem cells led to different types of brain tumors. Deletion of 
PTEN/Tp53 in adult sub-ventricular stem cells generated gliomas, although the deletion of 
Rb/Tp53 and Rb/Tp53/PTEN induced primitive neuroectodermal tumors (PNET) [7]. 
Progenitor cells and astrocytes may also considered as the origins of malignant glioma. It has 
been shown that the transfer of activated forms of Akt and KRas into Nestin-expressing neural 
progenitor cells led to tumor development, although this was ineffective in GFAP-expressing 
astrocytes. Ink4a/Arf are tumor suppressors that can activate Rb and p53. The loss of 
Ink4a/Arf was shown to enhance the capacity of KRas and Akt in the progenitor cells to form 
tumors. Moreover, the combination of Ink4α-Arf loss and KRas/Akt activation was effective 
in astrocytes and increased the incidence of tumor formation [8]. This indicates that oncogene 
activation and suppressor loss are important in the dedifferentiation of progenitors and 
astrocytes. 
1.2 DIAGNOSIS 
Glioblastoma occurs more frequently in the frontal lobe, compared to temporal and parietal 
lobes, mostly with headache and seizure symptoms. The current diagnosis, surveillance and 
therapeutic monitoring mainly depend on computed tomography (CT) and magnetic 
resonance imaging (MRI) scan, and histological examination. 
MRI scan is a primary tool for glioblastoma diagnosis. MRI provides higher resolution multi-
planar structural information. After MRI scanning, histological examination provides a 
definite diagnosis of glioblastoma. The tissue is collected after surgery, fixed, paraffin 
embedded, and stained with H&E as well as for some molecular biomarkers. As the name of 
multiforme suggests, glioblastoma is characterized by the presence of poorly differentiated 
pleomorphic astrocytic cells with frequent nuclear atypia and mitotic figures. There is often 
enhanced neo-angiogenesis, necrosis and pseudopalisading necrosis. Macroscopically, the 
central area is often yellowish necrosis from myelin breakdown, and is surrounded by 
peripheral grayish tumor cell areas, with multiple old and recent hemorrhages [9].  
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1.3 THERAPEUTIC APPROACHES 
Current therapeutic approaches for glioblastoma are surgical resection, followed by adjuvant 
radiotherapy and chemotherapy, as well as treatment with alternating electrical fields [10]. 
Surgical resection plays an important role in both the diagnosis and treatment of the 
glioblastoma by reducing the tumor load and providing tissues for histological and molecular 
diagnosis. Nowadays, more advanced techniques have been developed to maximize extension 
of resection and optimize the safety during surgery, such as operation by using intraoperative 
MRI or ultrasound, electrophysiological monitoring by using electrodes, functional brain 
mapping by awake brain mapping techniques, and maximizing tumor visualization by using 
fluorescent markers such as 5-aminolevulinic acid under blue light, or fluorescein in white 
light. 
Radiation therapy has improved the patients’ survival in glioblastoma [11]. The treatment is 
usually initiated 3 to 4 weeks after surgery and lasts for 6 weeks, with a cumulative absorbed 
dose of 60 Gy. Full-course radiotherapy with concurrent and adjuvant chemotherapy are 
commonly used in patients with good status, however abbreviated course of 
“hypofractionated” radiotherapy with concurrent and adjuvant chemotherapy is proper for 
elderly patients with bad performance and poor prognosis. 
Chemotherapy is another approach for treating glioblastoma. Temozolomide (TMZ) is a 
DNA-alkylating agent that can cross the blood-brain barrier (BBB) and achieve proper 
concentration in brain. TMZ concomitant to radiotherapy followed by maintenance TMZ 
treatment has become a standard care for patients with glioblastoma. TMZ leads to DNA 
strand breaks by adding methylation in DNA residues, such as N7-methylguanine, N3-
methyladenine, and O6-methylguanine, if they are not repaired by O6-methylguanine-DNA 
methyl-transferase (MGMT). Thereby the MGMT promoter methylation is a good prognostic 
marker for TMZ treatment. However, TMZ treatment in low-grade glioma has a risk to 
induce transformation to an aggressive high-grade glioma by induction of hyper-mutation and 
hyper-methylated status [12]. In addition, an anti-angiogenic agent (anti-VEGFA, 
bevacizumab), is used in glioblastoma patients. Low dose of bevacizumab together with 
standard radiotherapy and chemotherapy is utilized to decrease cerebral edema. The 
combination of bevacizumab with hypofractionated radiotherapy improved overall survival in 
elderly compared with radiotherapy alone, although this benefit was not observed in primary 
glioblastoma [13, 14]. 
Tumor Treating Fields (TTFields) is a new care approach in newly diagnosed glioblastoma 
patients. The mechanism is that it interferes with polar organelles and inhibits cell division by 
forming electrical fields of 200 Hz, and also induces anti-glioma immune response. Patients 
that received adjuvant TMZ and TTFields after initial treatment with TMZ/radiotherapy 
showed longer survival than those treated with TMZ alone [15, 16]. 
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1.4 GENOMIC ALTERATIONS IN GLIOBLASTOMA 
Current technologies such as large-scale genomic DNA analysis have eluded to the genetic 
evolution of glioblastoma. According to comparative genomic hybridization (CGH), the gain 
of chromosome 7p, with the epidermal growth factor receptor (EGFR) locus and the loss of 
chromosome 10q, with the phosphatase and tensin homologue (PTEN) locus are the most 
frequent alterations [17]. Besides this, gene mutations such as IDH, p53, PTEN, and their 
involved signaling pathways, including RTK/RAS/PI3K, p53 signaling, and RB signaling are 
critical in gliomagenesis [18] (Figure 2).  
 
Figure 2. Frequent genetic alterations in three critical signaling pathways. Adapted from [18], with permission. 
 
IDH mutations 
The main function of IDH1 is to convert isocitrate to α-ketoglutarate (α-KG), while the co-
factor nicotinamide adenine dinucleotide phosphate (NADP+) is oxidized to NADPH. 
However, the mutated IDH reduces α-KG to 2-hydroxyglutarate (2-HG) instead, and 
produces NADP+ from NADPH. The increase of 2-HG and reduction of α-KG can promote 
tumor development in several ways, such as blockade cell differentiation [19], activation of 
hypoxia-inducible factor 1α (HIF1α) and its downstream factors [20], and induction of tumor 
angiogenesis [21]. In glioblastomas, IDH1/2 mutations can be found in up to 5% of primary 
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glioblastoma cases, whereas it is present in almost 80% of secondary glioblastoma [22]. IDH 
mutations are also linked to epigenetic alteration of cytosine-phosphate-guanine (CpG) island 
methylator phenotype (G-CIMP) [23]. 
p53 mutation 
The ARF-MDM2-p53 pathway has been found deregulated in about 87% of glioblastomas 
[18]. Common mutations include missense TP53 mutations, deletion of CDKN2A/ARF, 
and/or amplifications of MDM2, and/or MDM4. MDM2 gene is located on chromosome 12q 
and is amplified in approximately 10-15% of glioblastomas [18]. TP53 mutations are more 
common in secondary (65%) than in primary (30%) glioblastomas [24]. p53 is a tumor 
suppressor and regulates DNA repair, cell senescence, cell death and metabolism [25]. In 
response to oncogene activation, ARF has the ability to inhibit the E3 ubiquitin ligase protein 
MDM2 that normally degrades p53, thus causing stabilization of p53. MDM2 is also a 
downstream target gene of p53 and p53 level is controlled thereby in a feedback loop. 
Inhibiting MDM2 from binding to p53 causes immediate stabilization of p53. Mutant p53 is 
unable to induce the MDM2 gene and mutant p53 may therefore accumulate to higher levels 
in tumors but this may depend on the mutation in question [26]. Moreover, a subset of p53 
mutants can be functional classified as gain-of–function (GOF) mutants, which was reported 
to attract microglia or monocytes inflammation in glioblastoma and correlated with shorter 
survival in patients [27]. 
PTEN mutation 
PTEN is a tumor suppressor gene and locates in chromosome 10q. The main function of 
PTEN is to negatively regulate the phosphatidylinositol-3-kinase (PI3K)/AKT pathways and 
control cell growth, metabolism and survival [28]. PTEN inactivation by mutation or deletion 
occurs in 36% of glioblastoma. The loss of PTEN promotes glioblastoma cells proliferation 
by increasing AKT/mTOR activity. In the cells with PTEN and wild type p53, they cooperate 
and enhance the tumor suppressive function of each other. PTEN is able to inhibit the 
degradation of p53, whereas p53 can activate PTEN by binding to its promoter [29, 30]. 
Conversely, in the cells expressing wild-type PTEN and mutant p53, PTEN can be said to 
have a tumor promoting properties. PTEN inhibits the degradation of mutant p53 by 
inactivation of MDM2 as well as direct stabilization of mutant p53 protein, where inhibition 
of PTEN suppresses cell proliferation and tumor growth [31]. 
EGFR amplification 
EGFR is located on chromosome 7p. EGFR amplification occurs in up to 40% of 
glioblastomas, and furthermore EGFR mutations (EGFRvIII) occur in half of tumors with 
amplified EGFR. EGFRvIII is a mutated form of EGFR with deletions in exons 2 and 7, that 
is a loss of 267 amino acids in the extracellular domain, and it shows less binding capacity to 
ligands [32]. In glioblastoma, wild type EGFR and EGFRvIII are always co-expressed, but 
EGFRvIII is more tumorigenic and activates the PI3K/AKT, RAS, and MAPK pathways in 
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cells. EGFRvIII and wild type EGFR form autocrine/paracrine loops in glioma cells, where 
the cells with EGFRvIII supply ligands, such as heparin binding epidermal growth factor 
(HB-EGF) and transforming growth factor α (TGFα), for the proliferation of cells with wild 
type EGFR [33]. 
PDGFRA amplification 
Platelet-derived growth factor receptor-α (PDGFRA) amplification is found in about 13% of 
glioblastoma. There are two main types of rearrangements associated with PDGFRA 
amplification. One is a gene fusion with VEGFR2, and the other one is an in-frame deletion 
of exon 8 and 9 (mutated PDGFRA). Mutant PDGFRA is a recurrent gene rearrangement 
occurring in 40% of the glioblastomas with PDGFRA amplification. Amplified PDGFRA has 
oncogenic properties in glioblastoma with elevated tyrosine kinase activity and transforming 
potential [34]. 
TERT promoter mutation 
Telomerase reverse transcriptase gene (TERT) locates on chromosome 5p15.33. TERT acts to 
maintain the length of telomeres by using its own RNA. TERT promoter (TERTp) mutation, 
where the two most frequent ones are C228T and C250T, activates TERT, resulting in 
elongated telomeres [35]. TERT mutations are frequent occurring in 69% of glioblastoma and 
related with higher risk of glioblastoma [36]. In cancer, increased telomerase expression by 
for example mutated telomerase promoter, or by an alternative lengthening of telomeres 
(ALT) promotes cells long-time survival [37]. 
MGMT hypermethylation 
MGMT is located on chromosome 10q26.3, which can remove alkyl adducts from the 
O6 position of guanine, therefore it has a function in DNA repair. MGMT hypermethylation 
is observed in approximately 50% of GBM and occurs at the cytosine-phosphate-guanine 
(CpG) island sites in the promoter area of MGMT [38]. Hypermethylation of MGMT silences 
the DNA repair function and results in base misrepair during DNA replication. In 
glioblastoma, patients with MGMT methylation have better response to alkylating 
chemotherapy[39].
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2. GLIOBLASTOMA HETEROGENEITY 
Tumor cell heterogeneity has become a hot topic of discussion in the glioblastoma field, and 
also in several other tumor types. Tumor cell heterogeneity refers to a variation in phenotypic, 
epigenetic, or genetic features. Due to the heterogeneity tumor cells bearing different 
abnormalities are predicted to respond differently to therapies. Therefore understanding of the 
heterogeneity is a strong prerequisite to advance personalized treatment and improve clinical 
outcomes. Heterogeneity can be seen at both an intertumoral and intratumoral level. 
Intratumoral heterogeneity can be considered at several different levels that to some extent 
overlap including cancer stem cells and differentiated cells, as well as cancer cells with 
distinct glioblastoma subtype gene expression signatures. 
2.1 INTERTUMORAL HETEROGENEITY-SUBTYPES 
Intertumoral heterogeneity refers to variation between tumors from different patients. Based 
on gene expression profiling, glioblastomas are classified into three molecular subtypes, 
namely classical, proneural, and mesenchymal [40, 41]. Each subtype contains gene 
expression signatures observed in different neural lineages, implying that different subtypes 
may have be associated with further phenotypic similarities to these lineages. 
The classical subtype has 100% frequency in gain of chromosome7 and loss of chromosome 
10. Tumors with the amplification and/or mutation in EGFR (EGFRvIII), located on 
chromosome 7, show high enrichment in classical subtype. Co-occurring with EGFR 
amplification, focal CDKN2A/CDKN2B deletion, which is located in 9p21.3, happens in 95% 
of classical subtype. Classical subtype has higher expression of the neural precursor and stem 
cell marker NESTIN, genes in the NOTCH pathway, such as NOTCH3, JAG1, and LFNG, as 
well as genes in sonic hedgehog signaling  (SHH) pathways, such as SMO, GAS1 and GLI2 
[40]. 
The proneural subtype displays characteristics including PDGFRA amplification, IDH1 and 
IDH2 mutations as well as TP53 mutations. Mutation of PDGFRA, or amplification at its 
gene location in the 4q12 locus happens in all subtypes, but more frequently in proneural 
cases compared to others, as well as high PDGFRA gene expression. IDH1 mutations 
(11/12), TP53 mutations (20/36) and loss of heterozygosity (LOH) (10/15) occur frequently 
in proneural subtype. Chromosome 7 gain and chromosome 10 loss occur in 54% of 
proneural cases. In proneural subtype, oligodendrocytic and proneural development genes, 
such as PDGFRA, OLIG2, DLL3, and SOX genes, are highly expressed, indicating its 
association with oligodendrocyte lineage cells [40]. 
The mesenchymal subtype is characterized by loss of NF1, accompanied by the focal deletion 
of a region at 17q11.2, and a majority of the samples have low NF1 gene expression level. It 
has been shown that among 20 samples with NF1 mutations, 14 of them belonged to the 
mesenchymal glioblastoma subtype. Among seven samples that had co-mutations of NF1 and 
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PTEN, six of them are observed in the mesenchymal subtype. Mesenchymal markers such as 
CHI3L1, MET, TNF, and several NF-κB pathway genes are higher expressed in this group 
[40]. 
However, combined omics results from tumor tissue analyses do not reliably to explain the 
complex cellular processes occurring within the glioblastoma tumor mass [42]. Some samples 
don't fall into either of these categories or seem to be composed of a mixture. This suggests 
that classification into three subtypes was not sufficient. Extensive evidence has recently 
shown that tumors are composed of many different cell clones, that is intratumoral 
heterogeneity. In 1987, Nistér et al. established diverse cell lines originating from the U343 
glioma tumor and showed they are phenotypically different although they have the same 
origin [43]. Recently, single cell based approaches have revisited the question of intratumoral 
heterogeneity in glioblastoma. Collectively, these reports indicate that intratumoral 
heterogeneity is complex and essential to study further. 
2.2 INTRATUMORAL HETEROGENEITY-GLIOMA STEM CELLS 
Cancer stem cells (CSCs) is a population of tumor cells that are able to sustain tumorigenesis 
[44]. During tumor development, CSCs differentiate to various non-CSC cells. CSCs have 
been assigned to have a high resistance to drug treatment and to cause tumor relapse. 
Therefore targeting of CSCs is a heavily researched therapeutic strategy. Nevertheless, 
potential dedifferentiation between a differentiated and a CSCs state, which is regarded as 
tumor cell plasticity and contributes to intratumoral heterogeneity, may hamper the success of 
CSCs targeting approaches. Moreover, glioma initiation cells (GICs), or tumor initiation cells 
(TICs) is a name that in certain contexts are interchangeably used for CSCs, have been 
reported to contribute to heterogeneity. Segerman et al. have shown that the drug and 
radiation sensitive GICs have a more proneural signature, while resistant cells have a more 
mesenchymal signature [45]. Therefore, better understanding of glioma stem cells (GSCs) 
and GICs would facilitate proper development therapeutic approaches targeting this tumor 
cell population. 
2.2.1 Intrinsic modulation of GSCs: genetic and epigenetic modification 
Many transcription factors have been shown important for GSC maintenance. Four 
transcription factors including POU3F2, SOX2, SALL2 and OLIG2 were identified to 
reprogram differentiated glioblastoma cells to stem-like tumor progenitor cells (TPCs), where 
50% of these cells expressed CD133. Moreover, these factors acquired H3K27 acetylation at 
their promoters, which sets them in an active state [46]. Forkhead box protein M1 (FOXM1) 
is also a transcription factor that regulates GSC. FOXM1 binds with the mitotic kinase 
maternal embryonic leucine zipper kinase (MELK), which functions to phosphorylate and 
activate FOXM1. The inhibitor of MELK, OTSP116, was shown effective in xenografts and 
promising therapeutic agent for glioblastoma [47]. FOXM1 also binds with PDGFA promoter 
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and promote PDGFA-STAT3 signaling to maintain the tumorigenicity of GSC [48]. YAP 
(Yes-associated protein) and MRTF-A (myocardin-related transcription factor A) can co-
activate Rho-mediated gene expression, and is required for GSC proliferation and 
tumorigenicity [49]. GSCs also display robust circadian rhythm for the growth depending on 
the core clock transcription factors, BMAL1 (Brain and muscle Arnt-like protein1) and 
CLOCK (Circadian locomotor output cycles kaput). The suppression of BMAL1 and 
CLOCK induced GSCs cell cycle arrest and increased apoptosis [50]. 
DNA methylation, as an epigenetic modification, has also been reported as a driver of CSC 
formation and maintenance. The methylation status depends on the DNA methyltransferases 
(DNMT1, DNMT3A, DNMT3B) and methylcytosine dioxygenases (the ten-eleven 
translocation, TET1 and TET2). DNMT3A mutation is the most common mutation that 
induces DNA methylation and confers self-renewal property of tumor cells [51]. TET 
proteins oxidize 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) to 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC). GSCs have been found with global loss 
of 5mC and 5hmC, accompanied by gain of 5fC and 5caC. Glioblastoma patients with low 
5hmC have been reported with shorter survival [52]. EZH2 (Enhancer of Zeste Homolog 2), 
is a polycomb repressor complex 2 (PRC2) methyltransferase subunit. Phosphorylation of 
EZH2 has been shown to methylate and activate STAT3 for GSCs maintenance [53]. 
Moreover, RNA methylation is important for GSCs. N6-methyladenosine (m6A) 
modification is a most prevalent RNA modification, which is catalyzed by methyltransferase-
like 3 and 14 (METTL3 or METTL14). Knockdown of METTL3/METTL14 increased GSCs 
self-renewal and tumorigenesis [54]. 
Therefore, a diverse set of transcription factors and methylation are involved in the regulation 
of GSCs. More knowledge on these factors will be helpful for targeting GSCs, for example, 
inhibition of methylation, such as by using DNMT inhibitor 5-azacytidine, would be effective 
in eliminating GSCs and get better response in glioblastoma patients. 
2.2.2 Extrinsic modulation of GSCs: microenvironment 
The perivascular niche is important for GSC maintenance. It has been reported that injection 
of GSCs in the subependymal zone of brain coronal organotypic slices induced a tumor cell 
response to endothelial niche signaling in the host brain [55]. Interaction between GSCs and 
endothelial cells (ECs) and/or pericytes has been shown to influence glioblastoma 
progression. In a PDGF-driven mouse model of glioblastoma, PDGF was able to induce 
endothelial nitric oxide synthase (eNOS) and activate NOTCH1 signaling to maintain GSC 
phenotype. Further, PDGF induces cell stemness via inhibitor of differentiation (ID). 
Inactivation of ID proteins decreases stemness in GSCs. Therefore a PDGF-ID-NO-NOTCH 
axis plays an important role in GSCs maintenance [56, 57]. The expressed NOTCH1 ligands 
Delta-like-4 (DLL4) and Jagged-1 (JAG1) in ECs can bind with NOTCH1 in GSCs and 
promotes tumor angiogenesis and growth [58]. Moreover, ECs secrete TGFβ and PDGF to 
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increase stemness genes expression, such as SOX2, OLIG2, BIM-1, and PROM1 (CD133) 
[59]. TGFβ from ECs helps GSCs to give rise to pericytes, which in turn protect endothelial 
cells and promote tumor growth. Removal of pericytes increases the sensitivity towards 
radiation or chemotherapy treatment and inhibits tumor growth [60]. Furthermore, the 
surrounding microenvironment increases inducible nitric oxide synthase (iNOS) production 
in GSC, and enhances sphere formation, tumorigenic potential. High iNOS correlates with 
bad prognosis [61]. 
Extracellular matrix (ECM), such as laminin, integrin and cadherin, interact with GSCs. 
Laminin α2 and α4 are expressed in mesenchymal cells, play a role in maintenance of GSCs, 
and contribute to tumor invasion and recurrence [62]. The laminin receptors, such as integrin 
ανβ3, ανβ5, α5β1, α3 and α6 have been shown expressed in glioblastoma. α5β1 is expressed 
in mesenchymal subtype glioblastoma, and it modulates survival of GSCs by negative 
regulation of p53 [63]. In addition, cadherin is important in cell-cell interaction and tumor 
invasion. N-cadherin is expressed in normal stem cells and functions to maintain progenitor 
state [64]. In glioblastoma, there is an alteration in cadherin expression, with down-regulation 
of E-cadherin that is associated with poor progression-free survival in glioblastoma, but with 
no effect on overall survival [65]. 
Hypoxic niche is a hallmark in glioblastoma. GSCs are enriched in hypoxic regions with 
activation of HIF-1 and HIF-2, which affects GSC self-renewal, proliferation and invasion. 
Hypoxia induces c-Met expression by HIF-1α, and enhances cell invasion by activation of 
hepatocyte growth factor (HGF) [66]. HIF-2 also regulates and promotes GSC phenotypes 
[67]. HIF-2α increases the expression of SOX2, KLF4, OCT4 and c-Myc [68]. Cells that are 
exposed to long-time hypoxia shift to stem-like state [69]. Hypoxic regions are heterogeneous 
with different degrees of oxygen tension, which may also contribute to spatial heterogeneity 
in glioblastoma. 
Besides, immune cells also contribute to the GSCs maintenance. I will describe it in the fourth 
part in this thesis. 
Above all, GSCs cooperate with surrounding microenvironment to maintain survival and 
growth. GSCs modification induced by intrinsic genetic and epigenetic changes, as well as by 
the microenvironment would contribute to the intratumoral heterogeneity in glioblastoma 
[70]. 
2.2.3 GSCs plasticity 
The bi-directional inter-conversion between stem and non-stem cancer cell populations is a 
contributing factor for glioblastoma plasticity [71]. In mammalian development, stem cells 
and progenitor cells can regulate transcription factors, chromatin regulators and associated 
cellular networks, resulting in forming different cell types. It has been shown that 
introduction of oncogenes into neural stem cells, progenitors and/or astrocytes in mice brain 
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generated malignant glioblastoma like tumors, accompanied by increasing expression of stem 
or progenitor cell markers compared to differentiation markers. This suggests a plasticity 
between differentiated cells and stem cell phenotype in glioblastoma [72]. Yamanaka et al. 
have made the stem cell plasticity to reality by generating induced pluripotent stem cells 
(iPSCs) from murine fibroblasts, where they transduced four transcription factors SOX2, Oct-
3/4, c-MYC, and KLF4 in fibroblasts [73]. Sura et al. further showed a core set of four 
transcription factors that coordinately bind and activate tumor propagating cells (TPCs) 
specific elements and sufficiently reprogram differentiated glioblastoma cells to induced 
TPCs [46]. The transition between non-GSCs and GSCs happens in response to 
microenvironment, such as perivascular niche, ECM, hypoxia and treatment. Bone 
morphogenetic protein 4 (BMP4) is a protein belonging to the TGFβ superfamily and 
important for early differentiation of embryo. Short time exposure of BMP4 on glioma stem 
cells decreased the tumor propagating capacity [74]. TMZ treatment in differentiated cells 
induces expression of Sox2, Oct4, CD133 and Nestin in GSCs, and these GSCs are more 
efficient to form tumor when intracranialy implanted in mice [75]. All of this indicates 
plasticity between GSC and non-GSC phenotypes in glioblastoma, which also is a cause for 
intratumoral heterogeneity. 
2.3 INTRATUMORAL HETEROGENEITY-GLIOMA CELLS 
2.3.1 Intratumoral heterogeneity in glioblastoma 
Intratumoral cancer cell heterogeneity in glioblastoma manifests that different clones with 
distinct genomic or epigenetic alterations, morphologies, and phenotypes coexist within 
individual tumors, with spatial and temporal distribution patterns [76]. It has been speculated 
that the intratumoral heterogeneity occurs during tumor evolution. Genetic alterations in 
receptor tyrosine kinase (RTK) genes, such as amplification of EGFR, MET, and PDGFRA, 
have been reported existing in the single glioblastoma. According to FISH analysis, these 
kinases are amplified in different cells in a mutually exclusive fashion, but they share 
common early genetic mutations, such as homozygous deletion of CDKN2A or TP53 
mutation. This indicates these cells are derived from a single precursor cell during tumor 
evolution. Several amplified RTKs coexisting in the same tumor suggests that combinational 
therapy, such as gefitinib (EGFR inhibitor) and imatinib (PDGFR inhibitor), is necessary to 
obtain complete inhibition of the PI3K signaling and suppress tumor growth [77, 78]. Ozawa 
et al. have shown that the common order of tumor evolution is initial gain of chromosome 7 
and loss of chromosome 10, then CDKN2A loss or TP53 mutation, and then alterations in the 
specific subtypes genes [79]. 
Sottoriva A et al. has uncovered this heterogeneity in glioblastoma by performing integrated 
genomic analysis on multiple biopsies taken from the same glioblastoma. They identified the 
chromosomal gain of EGFR and loss of CDKN2A/B in the early stage during cancer 
progression, however gain of PDGFRA and loss of PTEN were later events. Moreover, they 
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noticed different subtypes, proneural, classical, and mesenchymal subtypes present in the 
same tumor by using the Verhaak classifier genes [80]. Proceeding this, Patel et al. performed 
single cell RNA-sequencing on single cells from the same tumor, and the data showed that 
the individual glioblastoma is composed of cell subpopulations that have different proneural, 
classical or mesenchymal subtype signatures [81]. Meyer et al.’s study focused on the 
functional profiling of different clones in glioblastoma. They found these clones display 
unique proliferation, differentiation, tumorigenic and drug response abilities. Also therapy 
resistant clones preexist in the untreated glioblastoma, and express higher genes involved in 
cell migration (MET) and angiogenesis (WNT17B, EGF) compared to the TMZ sensitive 
clones [82]. 
2.3.2 Proneural to mesenchymal transition (PMT) 
Some cancer cells reversibly transition between different phenotypic states to contribute to 
tumor growth, named plasticity [83]. Deeper knowledge on the plasticity may lead to new 
potential targets for glioblastoma treatment and to new ways of confronting resistance. 
Currently, many studies have reported genetic alterations and signaling mechanisms that 
results in glioblastoma phenotype plasticity, where proneural to mesenchymal transition 
(PMT) is most studied. Ozawa et al. have shown PDGFA and PTEN are major drivers of 
glioblastoma. PDGFA was sufficient in the initiation of proneural-like gliomas, which was 
enhanced by PTEN loss. However, this proneural phenotype could be induced to a 
mesenchymal subtype by additional NF1 loss, suggesting mesenchymal subtype evolves from 
a proneural precursor [79]. Anti-angiogenic therapy (bevacizumab) provokes aggressive 
treatment resistant clones, which is associated with mesenchymal subtype, indicating that 
PMT may be an effect of anti-angiogenic therapy [84]. Many signaling pathways such as 
STAT3 and C/EBPβ, Hippo pathway TAZ, as well as the NF-κB pathway have been shown 
to be involved in PMT [85-87].  
STAT3 and CEBPB, as well as bHLH-B2, FOSL2, ZNF238 and RUNX1, are identified as 
master regulators in mesenchymal gene expression signature [86]. Halliday et al. found that 
radiation rapidly induces mesenchymal transition via the up-regulation of STAT3 and CEBPB 
in glioma [88]. The Janus kinase 2 (JAK2) is a STAT3 activator. JAK2-STAT3 has been 
shown to regulate many cellular processes in glioblastoma. Combination of JAK inhibitor 
AZD180 with radiation, compared to radiation alone, results in better survival in mice [89]. 
TAZ is a downstream factor of the Hippo pathway. It is a master regulator in PMT according 
to Bhat’s study, where TAZ expression is lower in proneural glioblastoma and low-grade 
gliomas, but higher in mesenchymal, and loss of TAZ in mesenchymal glioma stem cells or 
overexpression in proneural glioma stem cells affects mesenchymal gene expression 
signature. Chromatin immunoprecipitation (ChIP) showed TAZ is directly recruited to the 
promoter of MES genes in a complex with TEAD (transcriptional enhanced associated 
domain). The co-expression of TAZ and PDGFB induced a mesenchymal tumor [87]. 
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NF-κB pathway is also involved in PMT. Bhat et al, reported a NF-κB dependent 
mesenchymal transition with an associated enrichment of CD44 expressing cells and a gain 
of radio resistance, where macrophage/microglia was the potential microenvironment 
regulator. In support of this, immunohistochemistry analysis showed positive NF-κB 
activation signal in MES regions and close to macrophage/microglia infiltration zone [90].  In 
Yin’s study, they showed an increased expression of transglutaminase 2 (TGM2) in 
glioblastoma perinecrotic region, induced by macrophage/microglia-derived cytokines via 
NF-κB signaling. TGM2 is an enzyme that catalyzes Ca2+-dependent protein crosslinking and 
increases GSCs differentiation to MES subtype by upregulation of TAZ, CEBPB and/or 
STAT3 [91]. CXCL1 is a chemokine and highly expressed in glioblastoma. It has been 
shown that overexpression of CXCL1 in glioma cells induced mesenchymal transition via 
activation NF-κB pathway and increased radioresistance [92]. 
Besides PMT, transition exists between other phenotypes. Olig2 is an early marker for 
oligodendroglial lineage progenitors correlated with proneural phenotype. The ablation of 
OLIG2 causes a phenotype shift from proneural towards classical phenotype with activation 
of EGFR signaling, which reduces tumor initiation and growth and makes gliomas sensitive 
to EGFR inhibition [93]. 
2.3.3 Glioblastoma plasticity and tumor recurrence 
Tumor recurrence following treatment is one of the causes for cancer mortality. The recurrent 
tumors are usually not sensitive to the original therapies since the genomic alterations are 
distinct from those in the initial tumor. There are two theories to explain the role of genomic 
alterations. First, based on the intratumoral heterogeneity, treatment sensitive clones would 
be removed as a result of the treatment, and then the remaining resistant clones grow up and 
form new tumors. In another theory, the cancer cell bulk will be killed, except for the cancer 
stem cells (CSC) since they display more drug-resistance. Then CSCs give rise to new cells 
and to regrowth of the tumor.  
Recently, multiregional sequencing efforts have been made by profiling multiple regions in 
the primary and recurrent tumors to elucidate the evolution of tumor recurrence. From that, 
both linear evolution (the recurred tumor share majority of mutations with initial tumor) and 
divergent evolution (the recurred tumor share minority of mutations with initial tumor) were 
identified. Johnson et al. have sequenced the exosomes from both initial and recurrent tumor 
resections from the same patient, and noticed that many mutations present in the initial tumor, 
such as TP53, ATRX, SMARCA4, and BRAF, were not detected in the recurrent tumor. 
Moreover, recurrent tumors after TMZ treatment show inactivation of the DNA mismatch 
repair (MMR) pathway, deregulation of RB pathway such as RB1 and CDKN2A mutations to 
inhibit cell cycle arrest, and activation of Akt-mTOR signaling, such as PIK3CA and PTEN 
mutations to active Akt hyperactivation [94]. Kim et al. further showed that glioblastoma 
recurrence at a distant location had more divergent drivers alterations than recurrence in the 
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same location as the initial glioblastoma, indicating that re-biopsy and re-profiling are 
necessary for the distally recurring tumor. In addition, primary glioblastoma with wild-type 
IDH1 rarely develop hypermutations after TMZ treatment in contrast to IDH1-mutant 
gliomas [95]. In summary, these studies provide explanations for the ineffective treatment in 
the recurred tumors, and more insights into the evolutionary process are critical for improving 
patient care. 
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3. CELL-TO-CELL COMMUNCATION IN THE HETEROGENEOUS 
GLIOBLASTOMA 
Cancer progression depends on cooperation between tumor cells and other neighboring non-
tumor cells in the microenvironment. The distinct cancer cell subsets may also cooperate with 
each other and contribute to the malignant phenotype [96, 97]. Quite a few studies have 
focused on the communication between glioblastoma cells and surrounding immune and 
vascular cells, whereas there are limited reports on interactions between different 
glioblastoma cells. Davis et al. have constructed a model for clonal interactions and 
demonstrated that clonal heterogeneity is an intrinsic property and influences each other, for 
example cancer clones cooperate and protect slow growing clones. Moreover, they noticed 
clones that are drug sensitive can obtain resistance when cooperating with the drug-resistant 
clones [98]. This indicates more understanding on cell-to-cell interactions will provide clues 
to further therapeutic targets. Cell-to-cell interaction happens in many ways. Here I will 
introduce secreted factors, direct cell-to-cell contacts, gap junctions, and extracellular vesicles. 
3.1 SECRETED FACTORS 
Secreted factors are important for the cells inter-communication, such as interleukins (ILs), 
Wnt ligand and HGF, and so on. The cell clone with EGFRvIII communicates and promotes 
the proliferation of surrounding wild type EGFR tumor cells by secretion of IL6 and 
Leukemia Inhibitory Factor (LIF) [99]. IL6 could activate NF-κB and induce the expression 
of prosurvival protein survivin (BIRC5). Moreover, IL6 was found to change the sensitivity 
to EGFR tyrosine kinase inhibitors (TKIs), an effect mediated by bromodomain protein 4 
(BRD4), suggesting that the combination treatment of TKIs and inhibition of BRD4 would 
benefit glioblastoma patients [100]. 
WNT ligands are secreted proteins and WNT pathway has been shown involved in cell 
stemness, invasion and angiogenesis in glioblastoma. Norrin, which is encoded by Norrin 
disease protein (NDP), is an atypical Wnt ligand that can bind with Frizzled receptor 4 (FZD) 
and activate Wnt signaling. Norrin has been shown to have suppressive and promoting 
functions in ASCL1lo and ASCLhi GSCs, with an activation of Wnt signaling and Notch 
signaling mechanisms, respectively. ASCL1 (Achaete-scute homolog) is a basic helix-loop-
helix transcription factor and used a proneural factor, and high and low expression cells 
exhibit different differentiation and invasion dynamics [101]. Protocadherin FAT1, a tumor 
suppressor-related gene that encode a cadherin-like protein, can antagonize WNT signaling 
by binding with β-catenin and inhibiting its nuclear translocation. The homozygous deletion 
of FAT1 has been found in 20% of glioblastoma and leads to aberrant Wnt activation during 
tumorigenesis [102]. 
HGF (Hepatocyte growth factor)/MET (The mesenchymal epithelial transition) signaling is 
also associated with poor prognosis in glioblastoma patients, with the downstream effects 
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such as MAPK, PI3K/AKT, STAT3, and NF-κB, resulting in cell proliferative, invasive, and 
survival capacity [103]. It has also been shown as a mechanism for the resistance to EGFR or 
VEGFR inhibitors during the tumor treatment [104, 105]. Moreover, it was shown that 
inhibition of c-MET decreased nuclear translocation of β-catenin, indicating there are 
overlaps between c-Met and Wnt-β catenin in glioblastoma [106]. 
3.2 CELL-TO-CELL CONTACT 
Direct cell-to-cell contact is another important mechanism in the communication between 
cancer cells. Notch signaling mediates direct cell-to-cell interaction via binding of NOTCH 
ligands (Jagged-1 and 2 and Delta-like 1,3,4) on one cell to NOTCH receptors (Notch 1-4) on 
the adjacent cell to induce the enzymatic cleavages of Notch intracellular domain (NICD). 
Then NICD travels to the nucleus and leads the upregulation of Hes and Hey family 
members. NOTCH1 has been reported to crosstalk with other pathways, such as NF-κB 
factors (P50, P52, P65, RelB, and cRel). NOTCH1 promotes glioblastoma progression 
through the binding of NICD to P65, and affects cell proliferation and apoptosis [107].  
Hippo-YAP pathway has also been shown to control cell proliferation. Some upstream 
modules, such as cell-cell contact, cell-matrix contact, and also some extracellular growth 
factors, can regulate hippo pathway. The activation of Hippo leads to activation of Lats1/2, 
which induces phosphorylation and degradation of YAP/TAZ in cytoplasm, resulting in 
suppression of cell proliferation [108]. YAP and TAZ are downstream transcriptional 
coactivators in the Hippo pathway, and have been shown to regulate EMT and tumor survival 
together with KRAS [109]. 
Bradykinin and its receptor B1R binding have also been reported to increase glioma cell 
migration via PI3K/Akt pathway. Bradykinin (BK) is a peptide that promotes inflammation 
and also modulates BBB permeability [110]. In the three-dimensional (spheroid) co-culture 
model of glioblastoma cells U87 and bone marrow derived mesenchymal stem cells (BM-
MSCs), U-87 expressed higher B1R and became more invasive upon stimulation of B1R 
agonist des-Arg9-bradykinin, compared to 2D mono-culture, indicating the importance of 
cell-to-cell contact during tumor progression [111].  
3.3 GAP JUNCTIONS 
Gap junctions connect glioma cells and form intercellular networks enabling intercellular 
communications over long distances. Gap junctions are composed of membrane proteins 
called connexins, that function to transmit intercellular calcium waves (ICW) and 
bidirectional exchange of ions, microRNAs or other small molecules between cells. 
Disruption of gap junctions will isolate cells from this network and become more sensitive to 
the treatment. 
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In 1997, Chosh and Singh reported the role of gap junctional channels in glioma cells 
communication, where they observed decreased proliferation and increased differentiation of 
C6 glioma cells after exposure to dibutyryl cyclic AMP (dbcAMP). Moreover, the 
differentiated cells had more fine processes, which increased the frequency of cell-to-cell 
communication more than the body-to-body contact in undifferentiated cells [112]. Another 
report stated that EGF stimulation increased migration of glioma cells, accompanied by a 
decrease of connexin 43 (Cx43) level to detach the glioma cells from neighboring cells [113]. 
The first gap junction inhibitor, INI-0602, which can cross the blood-brain-barrier, renders 
glioma cells more sensitive to TMZ treatment through activation of JNK pathway [114]. 
Furthermore, gap junction is involved in transferring microRNA between cells. For example, 
enhanced gap junctions by retinoic acid treatment helped transferring microRNA-124-3p to 
adjacent glioma cells, which augmented the anti-proliferative function of miR-124-3p in 
glioma cells, whereas inhibition of gap junction eliminated this function [115]. 
3.4 EXTRACELLULAR VESICLES 
The extracellular vesicles (EVs), which are carriers of oncogenic drivers, microRNA and 
proteins, are found differentially expressed in glioblastomas of distinct subtypes, and also 
mediate cell-to-cell communication. EVs are accessible in biofluids, and are suggested as 
biomarkers in glioblastoma and may influence stem cell hierarchy and tumor 
microenvironment [116]. EVs in glioblastoma are involved in tumor cell proliferation, 
invasion, angiogenesis, and treatment resistance [117]. 
EVs from glioblastoma cells have been reported to induce the transformation of NSCs to 
tumor-promoting cells, with increased tumor proliferation and migration capacity [118]. 
EGFRvIII-transformed glioma cells, relative to EGFRvIII negative cells, are enriched with 
focal adhesion related proteins and pro-invasive proteins (CD44, BSG, CD151). These cells 
can deliver the oncogenic property to neighboring glioma cells [119]. The EVs from 
glioblastoma cells also mediate delivery of microRNA and non-coding RNAs that are 
conserved in cell cycle, PI3K/Akt and P53 pathways, such as miRNA-21. MiRNA-21 has 
been found enriched in the cerebrospinal fluid (CSF) from recurrent glioma patients, and is 
positively correlated with brain metastasis and tumor recurrence [120, 121]. EVs produced in 
proneural and mesenchymal GSCs are different. EVs from proneural GSCs have less 
exosomal markers, whereas EVs from mesenchymal GSCs express more canonical CD9, 
CD63 and CD81 tetraspanins, and are more efficiently internalized by endothelial cells to 
stimulate endothelial cell growth [122]. Furthermore, EVs play a role during drug treatment. 
It has been shown that resistant tumor cells can secrete apoptotic extracellular vesicles 
(apoEVs), which contain spliceosome components, such as RBM11, to alter RNA splicing of 
MDM4 and Cyclin D1 in the surrounding recipient cells, and rendering them more 
proliferative and oncogenic [123]. Ionizing radiation also induces export of miR-603 through 
EVs, resulting in suppressing expression of insulin-like growth factor (IGF), IGF1R and 
MGMT, and acquiring radiation resistance in GSCs [124]. 
 18 
In summary, the direct and indirect communication between cancer cell and cancer cell are 
important for the whole tumor growth and treatment resistance. Since glioma cells represent 
different gene expression subtype signatures even in the individual glioblastoma, their 
crosstalk signaling between each other would be more interesting to investigate. Thereby, a 
proper glioblastoma cell culture models needs to identify the complexity of the intratumoral 
heterogeneity. 
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4. MICROENVIRONMENT IN GLIOBLASTOMA 
Glioblastoma is an intratumorally heterogeneous tumor that contains not only tumor cells but 
also non-tumor cells, such as immune cells, astrocytes, and vascular cells, constituting the 
tumor microenvironment. The tumor microenvironment plays an important role in 
glioblastoma pathogenesis and progression. 
4.1 IMMUNE CELLS 
Immune cells, including macrophages, dendritic cells, and T cells, perform a defense function 
in normal physiology and in the early stages of tumor development. However, during tumor 
progression, the tumor cells produce factors that subvert immune cells to a more tumor 
protective phenotype, that is to protect the tumor from various immunosurveillance 
mechanisms [125].  
4.1.1 Tumor-associated macrophages/microglia (TAM) 
Tumor-associated macrophages/microglia (TAMs) represent the majority of the immune cell 
population that accounts for an estimated 40% of the tumor mass in glioblastomas [126, 127]. 
TAMs are composed of bone marrow derived monocytes (BMDMs) and resident-brain 
microglia cells. BMDMs come from monocytes in the blood and are replenished from blood 
monocytes. During tumor progression, the blood brain barrier is interrupted and monocytes 
are then attracted to the tumor by monocytes chemo-attractant proteins (MCPs), such as 
CCL2, CXCL12, CX3CL1, and glial cell-derived neurotropic factor (GDNF), and 
differentiated into macrophages [127]. Microglia are dispersed throughout the brain. It was 
reported to have developed from immature yolk sac runt-related transcription factor 1 
(Runx1)-positive progenitors, and responsible for pathogen clearance and synaptic processes 
maintenance [128, 129]. During gliomagenesis, microglia are recruited to and by 
glioblastoma cells and establish a feed-forward cellular circuit to drive tumor growth [127]. 
Microglia is not replenished from the mononuclear hematopoiesis, and the maintenance 
depends on self-renewal of resident cells in CNS [129]. In recent years, there have studies on 
how to distinguish BMDMs and microglia. Trans-membrane protein 119 (TMEM119) was 
shown expressed at a high level on microglia [130], and ITGA4 /CD49D was identified as a 
marker for BMDMs [131]. 
TAMs play an important role in glioblastoma progression and invasion, presumably through 
several mechanisms. TAMs promote the proliferation and invasion of glioblastoma cells by 
secreted factors, such as IL1β, TGFβ1, MMP2, MMP9 and CCL5 [127, 132-134]. TAMs 
suppress T-cell activation, and induce T cells producing less pro-inflammatory cytokines and 
express low level of CD80, CD86 and CD40 [135]. Moreover, TAMs affect angiogenesis and 
are associated with resistance to anti-angiogenic therapy, such as by bevacizumab [136]. 
Targeting TAMs is a promising emerging experimental therapy for glioblastoma. Colony 
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stimulating factor (CSF) is a factor that is important for macrophage growth and survival. 
Hence inhibition of colony stimulating factor-1 receptor (CSF1R) has been tested in many 
studies and it reduces glioblastoma growth and prolongs overall survival. Meanwhile, CSF1R 
inhibition induces glioblastoma cells to secret granulocyte-macrophage CSF (GM-CSF) and 
interferon-γ (IFN-γ), which increase the phagocytic function in macrophages, and enhance 
their efficiency in decreasing tumor [137]. Although treatment by CSF1R inhibition prolongs 
overall survival, tumors recur in more than 50% of mice via activation of IGF1/PI3K 
pathways. Together with blockade of IGF1/PI3K pathways, CSF1R inhibition significantly 
prolongs overall survival in recurrent tumors [138].  
4.1.2 T lymphoid cells 
The function of T cells in glioblastoma attracts more attention with the development of 
immunotherapy. Previous studies have shown that both CD8+ T effector cells and suppressor 
cells (Treg) exist in glioblastoma [139]. T cells stay in an exhaustion status in tumors, which 
is mediated by the transcription factor nuclear factor of activated T cells (NFAT). NFAT 
synergizes with activator protein 1 (AP1) and promotes T cell activation, however in the 
absence of AP-1, T cells go to an exhaustion status by binding other factors [140]. The 
activation of “Immune checkpoint” protein is another cause of T cells exhaustion, such as 
Programmed Death 1 (PD-1), cytotoxic T lymphocytes associated molecule 4 (CTLA4), T 
cell immunoglobulin 3 (TIM3), and Lymphocyte activating 3 (LAG3), which inhibit T cell 
proliferation after binding with their ligands. Moreover, the expression of PD-1 or CTLA4 on 
T cells affects metabolism by decreasing Glucose transporter 1 (GLUT1), an important 
molecule for glucose uptake. Hence T cells use more glycolysis and produce less ATP, 
further leading to T cells exhaustion [141]. Studies have shown that the combination of PD-1 
and TIM3 antibodies reduces tumor progression in the GL261 glioma model [142]. In 
another study it was found that the Programmed Death-Ligand 1 (PD-L1), the ligand of PD-1, 
is increased in mesenchymal glioblastomas [143], and as we know that higher PD-L1 is 
related with worse outcomes [144]. Importantly, treatment with PD-1 or PD-L1 inhibitors 
demonstrates significant survival advantages in preclinical studies [145, 146]. 
Treg is another population of lymphoid cells that is increased in glioblastoma. Treg has a 
function to suppress T-cell antigen specific response, and the amount of Treg is inversely 
correlated with patient survival in glioblastoma. Conditioned media from glioblastoma cells 
increases Treg cells expansion, for example CCL2 produced by macrophages and microglia, 
and CCL22 secreted by glioma cells are critical for Treg recruitment in the tumor 
environment [147, 148]. Indoleamine 2,3-dioxygenase (IDO) is an enzyme that is able to 
inhibit T cells proliferation and induce Treg cells, shows high expression in glioblastoma 
[149]. Combinational treatment of IDO inhibition with TMZ prolonged survival in a murine 
glioma model [150]. Moreover, IL2-STAT3 signaling activation contributes to Treg cells 
expansion. Inhibition of STAT3 by inhibitor STX-0119 decreases Treg prevalence and 
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increases tumor-infiltrating-T cells in TMZ resistant glioblastoma cells [151]. 
4.1.3 Dendritic cells (DCs) 
Many immunotherapies have focused on activating CD8+T cells by CAR-T or checkpoint 
inhibitors, however these therapies may be less effective based on the low level of tumor-
infiltrating lymphocytes (TILs). DCs therapy may have advantages in the low immunogenic 
tumors. DCs are one type of antigen-processing cells (APCs), which can process or present 
antigens to T cells or B cells to induce immune response. Many factors from the tumor cells 
or tumor microenvironment have been found to suppress DCs activation, such as VEGF, 
TGFβ, IL10 and CSF1 [152]. In glioblastoma, NF-E2-related factor 2 (NRF2) was found to 
be highly expressed in DCs, which is a transcription factor that regulates cellular defense 
against oxidative stress, and represses inflammation. Conditioned media from glioblastoma 
cells induced NRF2 expression in DCs and suppressed DCs maturation. In addition, NFR2 
was reported to suppress the function of macrophages and facilitated immune escape [153, 
154]. 
Dendritic cell vaccine (DCV) is a DC-based immunotherapy that induces anti-tumor T cell 
response. DCV has been studied in some cancers such as melanoma with promising results 
[155]. In the 90s, DCVs have also been tested in N32 and 9L rat glioma cell lines. Both cell 
lines showed effective response in cytotoxic CD8+T cell immunity. Toll-like receptor (TLR) 
agonists, such as imiquimod, could enhance DCs activation and T-cell immune responses. 
Combination treatment comprised of DCV and TLR agonists has been reported as a safe and 
useful adjuvant therapy to the traditional radiotherapy and chemotherapy in newly diagnosed 
and recurrent glioblastoma patients, with prolonged median survival of 31.4 months [156]. 
DCV can also induce a shift from Treg cells to Th1/Th17 cells. Together with immunogenic 
cell death (ICD) that is able to induce Th1 immunity, DCV has generated better immune 
response in preclinical glioma models [157]. 
4.2 TUMOR-ASSOCIATED ASTROCYTES (TAA) 
Astrocytes are glial cells that account for 50% of the brain cells. They are important in many 
physiological processes. Astrocytes are components in the structure of the blood-brain-barrier 
(BBB), where the end feet of astrocytes bind tightly with endothelial pericytes to maintain the 
vasculature [158]. During CNS damage, the induced astrogliosis supports tissue repair, where 
astrocytes alter their properties and become known as reactive astrocytes, with upregulation 
of the astrocytes-specific intermediate filament protein glial fibrillary acidic protein (GFAP), 
and of some growth factors and inflammatory factors such as brain derived neurotrophic 
factor (BDNF), CCL2 and IL6 [159]. In glioblastoma, astrocytes are involved in promoting 
tumor cell proliferation, invasion, and affecting treatment sensitivity [160]. When co-
culturing astrocytes and glioma cells, astrocytes promote glioma cells proliferation and 
decrease chemotherapy-induced apoptosis [161, 162]. Glioblastoma cells produce receptor 
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activator of NF-κB ligand (RANKL) to activate NF-κB pathway in astrocytes, and induce 
astrocytes to become tumor-associated astrocytes (TAAs). Then TAAs secrete TGFβ to 
further promote glioblastoma cells proliferation and invasion [163]. Other factors from 
reactive astrocytes also support glioblastoma cells, such as growth differentiation factor 15 
(GDF-15), which belongs to the TGFβ superfamily. GDF-15 is abundant in glioblastoma 
patients’ cerebrospinal fluid and correlated with shorter survival. The overexpression of 
GDF-15 promotes glioblastoma growth [164].  
Furthermore, reactive astrocytes also play a role for brain metastasis from different primary 
tumor sources. Active STAT3 in reactive astrocytes correlated with poor patients’ survival. 
Blocking of STAT3 reduced experimental brain metastasis of other tumors [165]. In addition, 
gap junctions are shown functional between astrocytes and in metastatic brain tumor cells. 
Connexin 43 is as a component of gap junctions which transfers the 2’3’-cyclic GMP-AMP 
second messenger (cGAMP) from tumor cells to TAAs, thus induces TAAs to secrete TNF 
and IFNα, which in turn activate STAT1 and NF-κB pathways in the metastasis tumor cells 
and induce their proliferation, invasion and resistance to chemotherapy [166]. Therefore, the 
combination of chemotherapies with gap junction or astrocyte inhibitors should be considered 
in further therapies for glioblastoma or brain metastasis from other tumors. 
4.3 VASCULATURE IN GLIOBLASTOMA 
The blood-brain-barrier (BBB) is an important structure in CNS to maintain the normal 
function. BBB is composed of endothelial cells, pericytes and astrocytic endfeet. Astrocytic 
endfeet have function to maintain the endothelial tight junctions and release vasoactive 
molecules to regulate vascular tone. In glioblastoma, the tumor cells use the perivascular 
space to invade and displace astrocytes, resulting in disruption of BBB integrity and 
permeability, which is named blood-tumor-barrier (BTB) [167]. BTB is characterized by 
aberrant distribution of pericytes and loss of astrocytic endfeet and neuronal connections. 
There are more immune cells in glioblastoma indicating the enhanced permeability of BTB to 
immune cells. 
Increased blood vessel formation is a striking feature of glioblastoma [168]. Interaction 
between GSCs and vasculature is bi-directional. GSCs promote angiogenesis by secretion of 
VEGF or CXCL12 and support GSCs growth [169]. Endothelial cells could be differentiated 
from GSCs via NOTCH1-signaling. Blocking of NOTCH1 pathway by γ-secretase inhibitor 
or shRNA decreased the transition from GSCs to endothelial progenitors, whereas anti-VEGF 
treatment inhibited maturation of endothelial progenitors to endothelium [170]. The GSCs 
differentiation to endothelial cells was further reported to occur via Tie2 signaling. Tie2 is a 
tyrosine kinase receptor that is mainly expressed in endothelium. After ionizing radiation 
treatment, GSCs were shown to generate more vessels, which was inhibited by using Tie2 
kinase inhibitor [171]. GSCs also contribute to pericytes formation to support vessel 
functions. GSCs are recruited to endothelial cells via CXCL12/CXCR4 signaling, where 
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GSCs can differentiate to pericytes via the induced expression of α-SMA via TGFβ signaling 
[60]. 
On the other hand, the perivascular niche (PVN) supports glioma cells and increases radiation 
resistance. Osteopontin, a CD44 ligand, promotes cancer stem cell phenotypes and 
aggressiveness via activation of CD44 signaling [172]. Endothelial NOS (eNOS) is highly 
expressed in tumor vascular endothelium, which has been shown to activate NOTCH-
signaling in PDGF-induced gliomas, and increase neurosphere forming capacity as well as 
tumorigenic capacity [56]. In co-culture of endothelial cells with glioblastoma cells, IL8 was 
shown to be secreted by endothelial cells, and promote glioblastoma growth and invasion by 
increasing CSCs frequency [173]. 
Above all, immune cells (macrophages, T cells and dendritic cells), tumor associated 
astrocytes and vasculature in the glioblastoma microenvironment have supportive function in 
the GSCs maintenance and tumor progression, meanwhile GSCs and glioma cells can induce 
their formation and infiltration, indicating the interaction between glioma cells and 
surrounding non-neoplastic cells can provide clues to new therapeutic targets. 
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5. SOX2 IN NORMAL DEVELOPMENT AND CANCER 
SOX2 is short for SRY (sex determining region Y)-box 2. Human SOX2 locates on 
chromosome 3q26.3-27 and encodes a protein of 317 amino acids. SOX2 is a transcription 
factor. In the N-terminus, it contains an HMG (high-mobility-group) domain that binds with a 
specific DNA sequence, the HMG domain is containing conserved functional elements 
including a nuclear export signal (NES) and a nuclear localization signal (NLS). The C-
terminus harbors the transactivation domain (TAD), and contains a phosphorylation-
dependent SUMOylation motif (PDSM). SOX2 plays a critical role in normal development 
and functions also in cancer [174]. 
 
Figure 3. Schematic diagram for structure of SOX2. 
5.1 SOX2 IN NORMAL DEVELOPMENT 
SOX2 is critical during the early embryonic development and is increasingly expressed from 
the 2-cell stage to the blastocyst stage. Absence of SOX2 causes embryonic lethality [175]. 
There are three germ layers during embryonic development, eventually giving rise to 
different tissue types in the body, which consist of endoderm (inner layer, develops to 
gastrointestinal tract, lung, liver, pancreas et.al), ectoderm (outer layer, develops to epidermis, 
hair, and also CNS, PNS et.al) and mesoderm (middle layer, develops to heart, muscle 
system, urogenital system et.al). SOX2 is able to induce axial stem cells to develop into 
central nervous system by activation of N1 enhancer, however, T-box Protein 6 (TBX6), 
which inactivates N1 enhancer and inhibits SOX2 expression, results in driving axial stem 
cells to mesoderm [176]. SOX2 is highly expressed in neural stem cells, but decreases during 
the differentiation into neurons and astrocytes. A deficiency of SOX2 caused failure in 
differentiation to mature GABAergic neurons [177]. Moreover, SOX2 is also involved in 
endoderm differentiation, such as the formation of trachea [178], stomach and esophagus 
[179]. 
SOX2 is highly expressed in embryonic neural progenitor cells (NPCs), but is also expressed 
in adult neural stem cells (NSCs). Together with OCT4 and NANOG, SOX2 has been shown 
to be essential for the propagation of undifferentiated NSCs in early development, where 
these factors collaborate and form regulatory circuits with auto-regulatory and feed-forwards 
loops to maintain the pluripotency and self-renewal function [180]. SOX2 is one of the 
Yamanaka factors (SOX2, KLF4, OCT4, c-MYC). Overexpression of Yamanaka factors in 
somatic fibroblast cells reprograms them to induced-pluripotent stem (iPS) cells [73]. SOX2 
also promotes oligodendrocyte differentiation by inhibition of miR145, which targets some 
SOX2
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pro-differentiation genes. Loss of SOX2 prevents terminal differentiation of oligodendrocytes 
but does not affect OPCs [181]. Since SOX2 marks adult stem cells in several epithelial 
tissues and promotes the generation of many types of cells to maintain tissue homeostasis, 
ablation of SOX2 has been shown to destroy the tissue homeostasis and lead to lethality 
[182]. Furthermore, SOX2 has been found subject to age-related decline of expression in 
many organs. For examples, the expression of SOX2 in peripheral blood mononuclear cells in 
elderly is less than in younger people, and its expression is inversely correlated with p16Ink4a. 
Therefore, SOX2 is also suggested as a biomarker for aging [183]. 
5.2 SOX2 AND CANCER STEM CELLS 
CSCs is a small population within the tumor bulk, with stem-like properties, high treatment 
resistance, and has a function in maintenance of tumor growth and tumor relapse after initial 
treatment [184]. CSCs have been shown important in the recurrence of many cancers, which 
eventually survive after chemotherapy and/or radiotherapy, differentiate to daughter cells and 
reconstruct the tumor, hence an efficient strategy to eradicate CSCs would be useful for 
cancer therapy. 
SOX2 has been reported as a key molecule that drives CSCs in many cancers. In skin 
squamous-cell carcinoma, SOX2+ cells are enriched in tumor-propagating cells with stronger 
tumorigenicity upon serial transplantation, especially of SOX2+CD34+ cells. Conditional 
deletion of SOX2 in the skin carcinoma leads to tumor regression [185]. In bladder, SOX2 is 
absent in normal urothelial cells, but it can be found in pre-neoplastic bladder cancer. Cells 
with SOX2 expression also express other bladder cancer markers, such as keratin14 (KRT14) 
and CD44v6 [186]. SOX2 has also been shown associated with CSC properties in colorectal 
cancer, with expression of CD24 and CD44 [187]. In lung squamous cell carcinoma (LSCC), 
SOX2 has been reported to cooperate with protein kinase C lota (PRKCι), both of them are 
oncogenes co-amplified in chromosomal region 3q26. SOX2 is phosphorylated by PRKCι 
and PRKCι-SOX2 signaling induces activation of Hedgehog signaling to maintain 
tumorigenic phenotype [188]. SOX2 can also antagonize Hippo pathway to maintain 
stemness in osteosarcoma [189]. Although SOX2 has a tumor promoting function in many 
cancers, it has been shown with an opposing effect in gastric cancer, where SOX2 expression 
is deregulated in cancer compared to normal tissue, due to hypermethylation of SOX2. SOX2 
exhibits an anti-proliferative and pro-apoptotic function via upregulation of PTEN and AKT 
dephosphorylation [190]. Above all, SOX2 is correlated with the maintenance of CSC 
properties and tumor progression in many different tumors. 
5.3 THE DOWNSTREAM SIGNALING TO SOX2 IN GLIOBLASTOMA 
SOX2 has been shown to positively correlate with the glioma malignancy grade, and to be 
higher expressed in the hyper-proliferative areas. Suppression of SOX2 in glioblastoma 
tumor-initiating cells (TICs) decreases tumorigenicity [191]. According to several 
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publications, SOX2 cooperates with many genes and functions in stemness maintenance. 
Hippo pathway plays a tumor suppressive role in cancer, where two Hippo activators, NF2 
and WWC1 (Kibra), exhibit an inhibitory function on the tumor-promoting factor YAP1. In 
osteosarcoma and glioblastoma, SOX2 was shown to interfere with the Hippo pathways by 
directly binding to NF2 and WWC1 and reducing their expression, leading to an increase of 
YAP to maintain CSCs and promote tumorigenesis. This suggests that targeting SOX2-
Hippo-YAP would be a therapeutic strategy in these tumors [189]. FOXG1 is a member of 
the forkhead box family of TFs, and it is one of the most overexpressed genes in 
glioblastoma-derived tumor spheres. FOXG1 and SOX2 have been shown in a cooperation 
way to restrict astrocyte differentiation and induce dedifferentiation to stem-like state by 
targeting cell cycle and epigenetic transcription factors, such as FOXO3, DNMT1, DNMT3B 
and TET3. The combination of Foxo3 loss and DNA methylation inhibitor 5-azacytidin was 
found to increase astrocytes dedifferentiation [192]. MiRNAs play a role during SOX2-
induced reprogramming and dedifferentiation. MiR-486-5p, as a SOX2-induced miRNA, is 
recently reported to relate with SOX2 expression and stem cell phenotype in glioblastoma. 
MiR-486-5p can target the tumor suppressor genes PTEN and FoxO1, indicating SOX2-miR-
486-5p axis plays a role to maintain the survival of glioblastoma stem cells. It has been 
shown that the delivery of miR-486-5p antagomirs in mice xenografts reduced tumor size and 
also enhanced the response to ionizing radiation [193]. 
5.4 THE UPSTREAM SIGNALING TO SOX2 IN GLIOBLASTOMA 
Many signaling pathways have been reported to maintain the SOX2 expression. SOX2 can be 
regulated by other genes and to keep cell stemness. GSCs prefer to reside in the perivascular 
region and get new nutrients for the self-renewal. They also locate along the white matter 
tracts. It has been reported that early invasive growth of GSCs along white matter tracts 
contributes to the poor outcome of glioblastoma treatment. The nerve fibers in white matter 
tracts secret the Notch ligand, Jagged1, which binds to Notch1 receptor in the 
CD133+Notch1+ GSCs, and induce SOX9 and SOX2 expression. In a positive feedback, 
SOX2 inhibits Notch1 methylation to increase Notch1 expression. Therefore, a NOTCH1-
SOX9-SOX2 positive-feedback loop in white matter tracts contributes to maintain GSCs 
[194]. A TGFβ-SOX4-SOX2 pathway also plays a role in maintaining GSCs. TGFβ directly 
increases SOX4, and SOX4 associates with the SOX2 promoter region and promotes SOX2 
expression. An inhibitor of TGFβ deprived of their tumorigenicity, which inhibition could be 
attenuated by transduction of SOX2 and SOX4. Meanwhile, TGFβ inhibition had a less lethal 
potency in an intracranial transplantation assay in glioblastoma, indicating that disruption of 
TGFβ-SOX4-SOX2 pathway would be a potential strategy against glioblastoma [195]. 
Osteopontin (OPN) is a secreted protein and can activate CD44 signaling in glioblastoma 
cells to acquire a stem cell phenotype. Targeting OPN in glioblastoma-initiating-cells was 
shown to decrease the expression of stemness transcription factors, such as SOX2, Nanog and 
Oct3/4, and abrogated tumorigenic potential in a xenograft mouse model [172, 196]. Wnt/β-
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catenin signaling is also connected with CSCs in glioblastoma. Inhibition of Wnt/β-catenin 
signaling increased TMZ sensitivity, and decreased stem cell markers such as CD133, Nestin 
and SOX2 [197]. CSC features also exist in circulating tumor cells (CTCs) in glioblastoma, 
exhibiting SOX2/ETn (early transposon promoter) transcriptional activation and expressing 
stemness markers such as SOX2, OCT4, and NANOG. CTCs are chemotherapy resistant, and 
have stronger tumorigenicity with activation of Wnt pathway [198]. SOX2 could be 
phosphorylated and stabilized by G1 cyclins and cyclin-dependent kinases (CDKs), and CDK 
inhibitor decreased SOX2 expression and inhibited sphere formation [199]. 
Some inhibitors have been found to down-regulate SOX2. PTPRZ and PTPRG, both belong 
to receptor-type protein tyrosine phosphatases (RPTPs), and are high expressed in sphere 
forming cells. Depletion of PTPRZ by knockdown or inhibitor NAZ2329 decreases SOX2 
expression and sphere formation [200]. Recently, a drug screen in human TMZ-resistant 
GICs was performed and a new pyrimidine synthesis inhibitor 10580 was identified to 
antagonize the pyrimidine synthesis enzyme dihydroorotate dehydrogenase (DHODH). In 
addition, this compound induces cell cycle arrest, apoptosis and GCSs differentiation by 
enhancing nuclear export of SOX2 [201]. Since the normal tissue and brain cells use salvage 
pathway for pyrimidine synthesis, this compound 10580 is suggested to be a glioblastoma 
therapy without side effects on normal cells [201]. 
In summary, SOX2 plays an important role in normal embryonic development and in adult 
tissue homeostasis. The absence of SOX2 would result in embryonic lethality. Moreover, 
SOX2 is a critical molecule during tumor development, although it may have opposed 
functions in different tumors. In glioblastoma, SOX2 is involved in gliomagenesis, tumor 
progression and therapy resistance via different pathways. Many factors regulate tumor 
progression via regulation of SOX2 and stabilization of SOX2. In summary, deeper 
understanding of the molecular and signaling pathways mediated by SOX2 may help to 
improve glioblastoma treatment.  
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6. SFRP2 IN NORMAL DEVELOPMENT AND CANCER 
SFRP2 is a secreted frizzled-related protein and contains a putative signal sequence, a 
frizzled-like cysteine-rich domain (CRD), and a conserved hydrophilic carboxy-terminal 
Netrin-like domain (NTN). CRD domain is homologous to the sites in Frizzled receptors that 
bind with Wnt proteins. SFRP2 has been shown to bind Wnt ligands or Wnt-receptor 
complex in different contexts, and exhibits either a promoting or an inhibitiory role in Wnt 
signaling. 
 
Figure 4. Schematic diagram for structure of SFRP2.  
6.1 CANONICAL AND NON-CANONICAL WNT SIGNALING 
There are three different main Wnt pathways, including canonical Wnt/β-catenin cascade, 
noncanonical Wnt/Ca2+ and noncanonical Wnt/planar cell polarity (PCP) pathways [202] 
(Figure 5).  
 
Figure 5. A schematic illustration representing canonical and non-canonical WNT signaling pathways. Adapted from 
[202], with permission. 
In the canonical Wnt/β-catenin pathway, Wnt ligands bind with Frizzled (Fz) receptor 
proteins and LRP5/6. Fz proteins are seven-pass transmembrane receptors with an 
extracellular N-terminal cysteine-rich domain (CRD). LRP5/6 is a single-pass transmembrane 
molecule. Upon Wnt ligand binding to the Fz receptor, the receptor interacts with and 
SFRP2
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phosphorylates Disheveled (Dsh) and GSK3β. GSK3β and casein kinase 1α (CK1α), 
subsequently induce the phosphorylation of LRP, and regulate Axin docking, resulting in the 
nuclear translocation and stabilization of β-catenin. Then β-catenin binds with the 
transcription factor complex T-cell factor (TCF)/lymphoid enhancer factor (LEF), and 
induces the transcriptions of genes. In the absence of Wnt, GSK3β and CK1α phosphorylate 
β-catenin and induce ubiquitination and degradation of β-catenin. In the nucleus, Groucho, 
instead of β-catenin, binds with TCF/LEF transcription factor and inhibits the transcription of 
Wnt target genes [202]. 
Many proteins have been reported to inhibit the canonical Wnt signaling pathway. The 
secreted Dickkopf (DKK1) is a secreted protein that antagonizes the Wnt pathway by binding 
with LRP6 and promoting LRP6 internalization and degradation to interrupt the Wnt-Fz-
LRP6 complex [203]. ROR2, another tyrosine kinase receptor with CRD motif, has been 
shown to bind with Wnt5a and inhibit the binding of Wnt with Fz receptors. Wnt5a/Ror2 
pathway represents a non-canonical Wnt signaling pathway [204]. Soluble Frizzled-Related 
Proteins (SFRPs) resemble the ligand-binding CRD domain, and were at the beginning 
presented as Wnt inhibitors by competing with Fz receptors for Wnt binding, such as Wnt1 
and Wnt8, but not Wnt5a [205, 206]. SFRPs have also been shown to enhance of the 
canonical Wnt/β-catenin pathway by direct interaction with Fz receptors or increase 
extracellular export of Wnt proteins [207]. SFRP2 has been reported to enhance Wnt-3a-
dependent LRP6 phosphorylation and β-catenin translocation to the nucleus [208]. 
Both non-canonical Wnt pathways do not involve β-catenin. Wnt/Ca2+ pathway controls the 
release of Ca2+ from the endoplasmic reticulum (ER) to cytosol. In this pathway, Wnt binding 
leads to the activation of either phospholipase C (PLC) or cGMP-specific phosphodiesterase 
(PDE). Activation of PLC induces IP3 cleaved from PIP2, and IP3 induces Ca2+ release after 
binding the receptor. Increased Ca2+ activates calcineurin and CaMKII, which activate 
NFAT, and affects cell adhesion, migration and tissue separation. However, activation of 
PDE has an inhibitory function in Ca2+ release by inhibition of protein kinase G (PKG) [202]. 
Wnt/PCP pathway controls the polarization of epithelial cells along the plane of the basal 
membrane. In this pathway, Wnt binds to Fz and other receptors, such as NRH1, Ryk, PTK7 
or ROR2, and recruits Dsh. In one way, Dsh forms complex with Disheveled-associated 
activator of morphogenesis 1 (DAAM1) and activates the small G-protein Rho and Rho-
associated kinase (ROCK). In another way, Dsh forms complex with RAC1 and activates 
JNK. Both ways result in regulation of the cytoskeleton [202]. 
Wnt3a, Wnt5a and Wnt7a are three most important Wnt family members. Wnt3a is a ligand 
that activates β-catenin signaling to induce expression of multiple genes for cell proliferation, 
such as c-Myc, CD44 and SOX9. Wnt5a mediates non-canonical Wnt/PCP signaling, and has 
been shown involved in atherosclerosis and vascular thrombosis [209]. Wnt7a is a most 
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studied Wnt ligand. It plays a role in both β-catenin and PCP signaling, and functions in 
embryogenesis and is involved in the pathogenesis of many cancers [210, 211]. 
6.2 WNT SIGNALING AND GLIOBLASTOMA 
Aberrant Wnt signaling is a driving force in many cancers. Many reports have shown the 
correlation of Wnt signaling with GSCs. FAT atypical cadherin 1 (FAT1) is a cadherin-like 
tumor suppressor protein that can bind with β-catenin and suppress its nuclear translocation. 
Somatic mutations of FAT1 have been reported to occur in 20.5% of glioblastoma. 
Inactivation of FAT1 promoted Wnt/ β-catenin and tumorigenesis in glioblastoma [102]. Wnt 
is also connected with other pathways, such as EGFR, and HGF pathways. c-Met is a 
receptor of HGF. It has been shown that GSCs with higher expression of c-Met have more 
activation of Wnt/β-catenin signaling [106]. Pleiomorphic adenoma gene like-2 (PLAGL-2) 
has been found high expressed in glioblastoma, and to activate the WNT/β-catenin pathway 
in GSCs. Overexpression of PLAGL-2 suppressed stem cell differentiation and induced the 
expression of stem cell marker Nestin [212]. Dickkopf (DKK1) is an inhibitor of Wnt 
signaling and suppression of DKK1 in GSCs promotes Wnt signaling. ASCL1, a 
transcription factor that is involved in GSC maintenance and propagation, has been shown to 
activate Wnt signaling by suppression of DKK1 [213]. Frizzle–related proteins (FRPs) are 
soluble proteins that can interfere the binding of Wnt with frizzle receptors (Fzd). The gene 
promoter hypermethylation of Wnt inhibitory proteins, such as sFRP1, sFRP2 and Naked 
(NKD2), has been shown to occur in 40% of primary glioblastoma [214]. Wnt inhibitory 
factor 1 (WIF1) could induce cell senescence and impede stemness and tumor growth [215]. 
Wnt signaling is also involved in tumor invasion. Overexpression of active β-catenin in 
glioblastoma cells increased ZEB1 expression and cell motility. Conversely, suppression of 
β-catenin in U87MG and LN229 suppressed tumor cell invasion [216]. In addition, 
knockdown of Wnt5a inhibited cell migration and recombinant Wnt5a stimulates migration 
by increasing the activity of MMP2 [217]. Oligodendrocyte precursors (OPCs), which 
express Olig2, PDGFRα, NG2 and other markers, are one source of glioblastoma. It has been 
reported OPCs produced Wnt7 signaling and affected the vascularization [218]. In addition, 
the interaction between OPCs and endothelial cells promoted OPCs migration via Wnt-
CXCR4 signaling [219]. 
Wnt signaling also contributes to treatment resistance of glioblastoma. It has been reported 
there are more cells with both active β-catenin (ABC) and SOX2 (ABC+/SOX2+) in 
radioresistant glioblastoma cells. The amount of these cells increased with additional 
radiotherapy, but cells became radiosensitive when using Wnt pathway inhibitor XAV 939 or 
siRNA [220], suggesting the combinational treatment of radiotherapy and inhibition of Wnt 
signaling should be considered in further treatment. 
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Many drug that target Wnt pathway has been tested in glioblastoma. Aspirin, a non-steroidal 
anti-inflammatory drug (NSAID), can inhibit cell proliferation and invasiveness by 
decreasing TCF/LEF promoter activity and target genes expression (c-MYC, Cyclin D1, and 
FRA-1) [221]. Diclofenac and Celecoxib, another two NSAIDs that can inhibit COX-1/2, 
have been shown to reduce the glioblastoma growth [222]. Both SEN461 and XAV939 are 
potent WNT signaling inhibitors, that can stabilize AXIN, increase phosphorylation and 
degradation of β-catenin [223]. However, their clinical effects have not been reported. 
6.3 SFRP2 AS AN ANTAGONIST OF WNT SIGNALING 
SFRP2 is primarily reported as a Wnt signaling inhibitor by preventing the binding of Wnt 
with Fz receptors [224]. SFRP2 enhances osteogenic differentiation potential by suppression 
of WNT1 and antagonizing the canonical WNT pathway [225]. In the progression of chronic 
obstructive pulmonary disease (COPD), exposure to cigarette smoke extract (CSE) induces 
SFRP2 expression, and SFRP2 further increases airway inflammation by inhibition of β-
catenin [226]. 
SFRP2 has been identified as tumor suppressor in many cancers with low expression level or 
hypermethylation of SFRP2. Down-regulation of SFRP2 shows a potent tumor-promoting 
effect in choriocarcinoma (CC). Decreased SFRP2 promotes cancer stemness and the 
epithelial-mesenchymal transition (EMT) process via activation of Wnt/β-catenin signaling 
[227]. Hypermethylation of SFRP2 is detected in stool and suggests to be a potential marker 
for colorectal cancer and precancerous lesions [228]. Hypermethylation of SFRP2 is also a 
frequent alteration in breast cancer [229], gastric cancer [230], and cervical cancer [231].  
SFRP2 can also promote tumors as a Wnt antagonist. In melanoma, SFRP2 was found to be 
secreted by aged fibroblasts and promote angiogenesis, tumor metastasis and treatment 
resistance, where SFRP2 functions as a Wnt antagonist, and decreased β-catenin and APE1, 
which renders melanoma cells more resistant to the targeted therapy [232]. In P53 mutant-
osteosarcoma (OS) patients’ samples, high SFRP2 has been shown to correlate with poor 
survival. Ectopic SFRP2 overexpression in osteoblast precursors promoted OS phenotype via 
increase of oncogenic FOXM1 and CYR61 expression. SFRP2 overexpression cells showed a 
decrease in Wnt3a-mediated canonical Wnt [233]. 
6.4 SFRP2 AS AN AGONIST OF WNT SIGNALING 
In many studies, SFRP2 is described to act as an agonist of Wnt signaling. SFRP2 regulates 
the extension of anaerobic glycolysis in mouse cardiac fibroblasts (CFs) through canonical 
Wnt/β-catenin signaling by increasing Wnt3a [234]. SFRP2 can also activate the non-
canonical Wnt pathway during vertebrate gastrulation, where SFRP2 promotes Ror2 
signaling by stabilizing a Wnt5a-Ror2 complex [235]. In the damaged tumor 
microenvironment, DNA damage of stromal cells activates NF-κB, which binds to the SFRP2 
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promoter and increases SFRP2 expression. Then SFRP2 can enhance Wnt16B/β-catenin 
signaling and promote therapeutic resistance [236]. 
SFRP2 has also been reported as a WNT agonist and promotes growth in some tumors. In 
renal cancer, SFRP2 has an oncogenic function and activates the canonical WNT pathway by 
decreasing the phosphorylation of β-catenin [237]. In breast cancer, SFRP2 was found to 
induce endothelial tube formation and angiogenesis via activation of the 
calcineurin/NFATc3, a non-canonical WNT pathway [238]. SFRP2 is also involved in the 
lung metastasis of breast cancer. The crosstalk between the cancer cells and lung epithelial 
cells induces SFRP2 expression in breast cancer cells, and promotes fibrillogenesis, which 
gives a support to the regrowth of cancer cells [239]. Moreover, SFRP2 could be considered 
as a potential therapeutic target. Fontenot et al. have shown that treatment with SFRP2 
monoclonal antibody decreased tumor volume in mice allografts with breast cancer cell 
MDA-MB-231, where they found the decreased activation of β-catenin and NFATc3, 
indicating SFRP2-Wnt signaling is important in breast cancer [240]. 
6.5 SFRP2 AND GLIOBLASTOMA 
The involvement of SFRP2 in glioblastoma has not been extensively explored. Majchrzak-
Celińska et al. tested the promoter methylation of WNT pathway regulators, including 
SFRP1, SFRP2, DKK1, PPP2R2B, SOX17 and DACH1 in 64 glioma samples, which 
contained 26 glioblastomas. They found that methylation of SFRP1 and SFRP2 was 
frequently occurring, with respectively 73.4% and 46.9%. But only SFRP1 promoter 
methylation predicted worse patient survival [241]. In one report ectopic expression of 
SFRP2 in glioma cells enhanced clonogenicity and resistance to serum starvation, as well as 
inhibited cell mobility by decreasing the expression of matrix metalloproteinase-2 (MMP-2) 
and tyrosine phosphorylation of β-catenin [214]. Conversely, SFRP2 has been shown as a 
tumor suppressor in another report, where overexpression of SFRP2 inhibited glioblastoma 
sphere formation and tumor growth in vivo. Mir22HG, which can target SFRP2, was found 
highly expressed in glioblastoma. Suppression of Mir22HG attenuated cell proliferation and 
tumor growth by inhibiting Wnt/β-catenin signaling, indicating SFRP2 is a Wnt antagonist in 
this context [242]. 
Above all, the effect of SFRP2 in different cells is distinct, and context depended, underlying 
these reports stating different activities. It is still inconclusive if SFRP2 acts as a WNT 
agonist or antagonist in glioblastoma. The net in vivo effect of SFRP2 in glioblastoma is thus 
still a very open question. But in support of further studies, it does affect key glioblastoma 
phenotypes, and is differentially expressed between glioblastoma cases. 
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7. PROX1 IN NORMAL DEVELOPMENT AND CANCER 
The Prospero-Related Homeobox 1 (PROX1) is a transcription factor, a protein of 82.3 kDa. 
The N-terminal part of PROX1 harbors a nuclear localization signal (NLS) and two nuclear 
receptor boxes (NRB). The prospero-domain in C-terminal contains a functional 
proliferating cell nuclear antigen (PCNA) interacting motif. PROX1 is essential for the 
development of several organs and knockout of Prox1 in mice embryos results in lethality 
due to multiple developmental defects [243]. 
 
Figure 6. Schematic diagram for structure of PROX1.  
7.1 PROX1 IN NORMAL DEVELOPMENT 
PROX1 has been shown to be critical in the development of several organs, especially in 
lymphatic system [243]. Many publications have reported the regulation of PROX1 during 
lymphatic development. PROX1 is a lymphatic endothelial cell (LEC) master transcription 
factor, where Wnt/β-catenin signaling is important during lymphatic vessels development. 
PROX1 has been shown to form a complex with β-catenin and enhance its signaling [244]. 
Together VEGFC, FLT4 and PROX1 could be involved in angiogenic sprouting and 
lymphatic formation, with haematopoietically expressed homeobox (HHEX) as their 
upstream regulator [245]. Moreover, depletion or hyper-activation of LEC-specific Hippo 
pathway molecular YAP/TAZ aggravates or attenuates the lymphatic formation by increasing 
or decreasing PROX1 transcription [246]. In addition, PROX1 is important in other organs. 
PROX1 can regulate sarcomere integrity and maintain the function of the heart [247]. It is 
also essential for skeletal muscle phenotype and myoblast differentiation by cooperation with 
the NFAT and NOTCH1 pathways [248]. 
PROX1 can be detected in different stages of brain development. At the prenatal stage in 
mouse, Prox1 is detected in subventricular zone and other regions in prethalamus and 
hypothalamus. Prox1 can be found in thalamus, the cerebellum, and the hippocampus in 
postnatal stage. However, Prox1 only remains its expression in the hippocampus and 
cerebellum in the adult. These different distributions of Prox1 indicates its role in brain 
development [249]. PROX1 was shown to be important in CNS development and 
neurogenesis by induction of differentiation of neural stem cells [250]. 
Many factors regulate or are regulated by PROX1 during neurogenesis. SoxC proteins, such 
as Sox4 and Sox11, were reported to bind with the promoter of PROX1 and activate PROX1 
in neurogenesis [251]. NOTCH1 signaling is important in the self-renewal of neural 
PROX1
Homeodomian Prospero domain N CN-terminal domian
NLS NRB PCNA
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progenitor cells (NPCs). PROX1 was shown to be induced in differentiated NPCs and inhibit 
NOTCH1 signaling, that is to maintain the balance between cell self-renewal and 
differentiation [252]. PROX1 is a target of β-catenin signaling. PROX1 enhances neuronal 
differentiation but is not required for survival of mature granule cells [253]. PROX1 has also 
been shown to be important for induction of neurogenesis in the dentate gyrus (DG), and has 
been shown to be indispensable in oligodendrogliogenesis in the SVZ [254]. 
Moreover, PROX1 has been shown to regulate the circadian rhythm and energy metabolism. 
It has been shown that PROX1 can form a complex with the estrogen-related receptor α 
(ERRα), BMAL1 and PGC1α and repress their transcriptional activity [255]. PROX1 also 
repress the activity of the retinoic acid-related orphan receptors (RORα and RORγ). 
Knockdown of PROX1 increases RORγ and its target clock genes Bmal1, and cryptochrome 
1 (Cry1), to control the clock and metabolic network [256]. Related to energy metabolism, it 
has been reported that the rs340874 single nucleotide polymorphism (SNP) in PROX1 is 
significantly correlated with the insulin level in the plasma, and the knockdown of PROX1 
decreased the insulin secretion, suggesting reduced PROX1expression is susceptible for 
type II diabetes [257]. 
7.2 PROX1 AND CANCER 
PROX1 is involved in tumorigenesis and progression, but has been reported to exert both 
oncogenic and suppressive properties. It promotes tumor progression and invasion in colon 
cancer cells [258, 259]. In the colorectal cancer (CRC), the loss of APC or CTNNB1 has been 
reported as the initial mutations, leading to activation of canonical Wnt/β-catenin pathway. 
Then elevated Wnt activity induces PROX1 expression. PROX1+cells were found with stem 
cell property in intestine adenomas, but not in normal intestine. PROX1 is important for the 
maintenance of stem cell population, and it inhibits annexin A1 to increase the expression of 
filamin A, which plays a role in DNA damage repair [259]. In addition, PROX1 can 
modulate metabolic adaption, and promotes colon cancer cell proliferation during hypoxia 
and nutrient deprivation, by suppressing the pro-apoptotic molecule BCL2L15 [258]. PROX1 
also interacts with nucleosome remodeling and deacetylase (NuRD) complex to suppress 
NOTCH1 pathway and differentiation in colon CSCs [260]. In breast cancer, PROX1 has 
been shown with tumor suppressive function that PROX1 is hyper-methylated and 
transcriptionally silenced [261]. Moreover, PROX1 inhibits tumor in esophageal cancer 
[262], pancreatic cancer [263], and neuroblastoma [264]. In hepatocellular carcinoma (HCC), 
the function of PROX1 is controversial. PROX1 has been shown with a correlation with 
differentiation score in the tumor, and the low expression was associated with bad prognosis. 
Suppression of PROX1 accelerated tumor cell growth [265]. It has reported that PROX1 
inhibits Twist expression, which binds with E-box of P53 promoter. Therefore PROX1 was 
suggested to inhibit tumor growth by induction of P53-depedent senescence [266]. Mir-670-
5p, which targets on PROX1, has been shown high expressed in HCC, and suppressed 
PROX1 expression to promote cell proliferation [267]. Conversely, in another report PROX1 
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expression in primary HCC has been shown correlated with worse survival. Knockdown of 
PROX1 suppressed cell invasion and tumor metastasis in mice xenografts, where PROX1 up-
regulated HIF expression and stabilized HIF-1α to promote epithelial–mesenchymal 
transition [268]. Moreover, PROX1 can enhance β-catenin activation and promote sorafenib 
resistance in HCC cells [269]. It is difficult to explain the opposite results. One reason may be 
different HBV infection states in HCC patients. 
Until now, there are not many reports on the function of PROX1 in glioblastoma. PROX1 has 
been detected in gliomas of different grades. By using immunohistochemistry, Elsir et al. 
showed 79% of Grade IV, 57% of Grade III, and 21% of Grade II gliomas contain cells that 
are strongly PROX1 positive. PROX1 was co-expressed with neural protein marker MAP2 
and βIII-tubulin in these cells, and these cells also had lower proliferation rates [270]. In 
grade II glioma, higher PROX1 is a predictor for worse survival, combined with IDH 
mutation and loss of chromosomal arms 1p/19q [271]. In grade IV, PROX1 was shown to 
have no correlation with survival in the primary glioblastomas, but higher PROX1 is a 
prognostic marker in the secondary glioblastomas with IDH-mutation and 1p19q non-
codeletion [272]. Another report showed overexpression of PROX1 in glioblastoma cell line 
increased cell proliferation and xenograft growth by activating NF-κB pathways [273]. These 
findings highlight the role of PROX1 during gliomagenesis, and the mechanism and function 
of PROX1 in glioblastoma should be further investigated. 
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8. PRESENT INVESTIGATION 
8.1 AIMS 
The general aim of this thesis was to investigate the mechanisms of intratumoral 
heterogeneity in glioblastomas: how the different glioblastoma subtypes transition, how the 
different clones inside the tumor communicate with each other and how the heterogeneity 
affects tumor treatment. 
Specific aims were: 
To study the regulators of glioblastoma mesenchymal transition 
To investigate the function of PROX1 in glioblastoma 
To identify the functionally distinct and interacting cancer cell populations in glioblastoma 
 
Figure 7. Schematic diagram illustrating the aims of this thesis.  
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8.2 RESULTS 
8.2.1 Paper I  
SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in 
glioblastoma 
Glioblastoma is an intratumorally heterogeneous tumor, with different proneural, classical 
and mesenchymal gene expression subtypes presented in individual tumors. A transition from 
non-mesenchymal to mesenchymal subtype cells has been reported to occur during tumor 
progression. In this study, we aimed to identify regulators that can mediate a transition 
between non-mesenchymal and mesenchymal gene expression subtype. We started with a 
CMap analysis on gene expression data from two separate datasets, 48 samples from HGCC 
and 45 glioblastoma cell cultures from CCLE, that were derived from cell cultures grown in 
defined neurosphere medium on laminin or in serum, respectively. We used this dual analysis 
approach to reduce the contribution of expression patterns that are connected to different 
culture conditions. In the CMap analyses, we identified SOX2 as a major gene expression 
pattern modulator for both the HGCC and the CCLE cultures in the group with non-
mesenchymal gene expression signature. 
We have previously defined two subsets of glioblastoma cell cultures, denoted Hesselager 
type A (non-mesenchymal, SOX2high) and type B (mesenchymal, SOX2low). Subsequently, 
we have named genes on average higher expression in type B cells as type B genes and in 
type A cells type A genes, respectively. In order to investigate if any of these genes 
specifically regulates the mesenchymal subtype, we performed an overexpression screen by 
overexpressing type B genes in the type A cell line U-2987, which originally has high SOX2 
expression, and monitored the levels of SOX2 expression. Here SFRP2 was identified as a 
SOX2 suppressor. Next, we generated RNA-seq data from these cells with and without 
SFRP2 overexpression and analyzed. We found that SFRP2 overexpression switched the 
cells from a non-mesenchymal to a mesenchymal gene expression pattern. SFRP2 was also 
found on average higher expressed in glioblastoma mesenchymal subtype in the TCGA 
samples, than in the proneural and classical subtype samples. Our phenotypic assays in vitro 
with the SFRP2 overexpressing cells further showed increased cell Matrigel invasion and 
decreased tumor sphere formation, cell proliferation, and altered levels of cell cycle proteins. 
Conversely, to investigate if these phenotypic changes could be reversely recapitulated in 
connection to SOX2, we overexpressed SOX2 in the cell culture U-2982, which original is of 
mesenchymal type and thus have low SOX2 levels. We found that SOX2 overexpression 
induced a transition from a mesenchymal glioblastoma subtype gene expression pattern to a 
proneural subtype pattern, and in connection increased the tumor formation and decreased 
Matrigel invasion capacity. In an analysis where we divided TCGA glioblastoma samples 
into four groups according to the median expression values of SFRP2 and SOX2, the 
subgroup with high SFRP2 and low SOX2 expression was enriched with mesenchymal 
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glioblastoma subtype cases and with shorter survival. 
To investigate the mechanism of SOX2 inhibition upon SFRP2 overexpression, we integrated 
CCLE gene expression profiling with RNA-seq data analyses from SFRP2 or SOX2 
overexpression cells followed by gene overexpression or knockdown modification of the 
potential mediator genes. KLF4 was identified as a candidate protein involved in the 
suppression of SOX2 by SFRP2. Using global protein tyrosine kinase analysis by Pamgene, 
PDGFR signaling was identified and we found PDGFRA was decreased and PDGFRB was 
increased by SFPR2 overexpression. Since SFRP2 has been regarded as both an agonist and 
an antagonist of Wnt/β-catenin signaling, we tested SOX2 expression after knockdown of 
CTNNB1 (β-catenin), however, it was apparently not involved in the inhibition of SOX2 by 
SFRP2. 
At the end, we conducted a spatial tumor tissue analysis where genes that were both 
positively correlated to and induced by SFPR2 were found to be higher expressed in 
vascularized tumor areas, whereas SOX2 positively correlated and induced genes were 
located in cellular tumor areas. Human protein atlas (HPA) staining also showed type A 
genes and type B genes distributed in cellular and vascular areas, respectively. In line with 
this, increased pro-angiogenic, pericyte and macrophage markers were identified in the 
vascular areas with high SFRP2 and low SOX2 expression. In support of the potential 
immunogenic effect, conditioned media from SFRP2 overexpression cells had a relatively 
higher capacity to increase CD206 expression in human monocytes, which is also known to 
be part of an M2-polarization phenotype. 
In summary, SFRP2 was identified to induce a mesenchymal gene expression pattern by 
suppression of SOX2 expression. SFRP2-induced and positively SFRP2-correlating genes 
were found at higher levels in the vascularized areas of tumor tissue, and in vitro was 
connected to a CD206 expression increase in macrophages. Overall, this study proposes that 
SFRP2 induces a glioblastoma subtype transition that is spatially confined to vascular tumor 
area and provides new insight into the regulation of related gene expression patterns in 
intratumorally heterogeneous glioblastomas. 
8.2.2 Paper II  
Reduced expression of PROX1 transitions glioblastoma cells into a mesenchymal gene 
expression subtype 
Prospero-related homeobox 1 (PROX1) is a transcription factor that is expressed and 
functionally active in some tumors, such as in neuroblastoma where it has a growth 
suppressive role [264]. In this study, we aimed to investigate the functional role of PROX1 in 
glioblastoma by performing integrated analyses of RNA-seq data derived from in vitro 
experiments and publicly available expression data from single cell sequencing experiments. 
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We started with analysis of a combined TCGA glioma data set, which contains grade II to 
grade IV gliomas. Grade IV gliomas (glioblastomas) showed lower expression of PROX1 and 
connection with worse overall survival compared with grade II and III gliomas, which 
showed higher PROX1 expression. In line with this, the group of glioblastoma patients with 
high PROX1 levels also showed better prognosis and were enriched for mesenchymal 
glioblastoma gene expression subtype tumors. We then analyzed the PROX1 protein 
expression in a panel of glioblastoma cell lines, and noticed that in most cells SOX2 and 
GFAP were higher expressed in PROX1 expressing cells and FN1 was higher in PROX1 
negative cells, with U-343 MGa and U-343 MG glioblastoma cells as examples, respectively. 
These two cell lines were used for subsequent generation of stable overexpression cell lines 
and RNA-seq analyses. 
We thus overexpressed PROX1 in U-343 MG and suppressed it in U-343 MGa. RNA-seq 
gene expression and gene set enrichment analysis showed PROX1 was connected with 
neurogenesis, cell proliferation, and epithelial-mesenchymal transition signatures. By 
comparing PROX1 regulated genes with glioblastoma subtype classifier genes, PROX1 
overexpression was found to decrease the support index for mesenchymal subtype and 
increase it for non-mesenchymal subtypes in U-343 MG. Conversely, PROX1 depletion in U-
343 MGa increased support index for mesenchymal subtype. Moreover, we found that 
PROX1 was higher expressed in HGCC cultures with a higher tumorigenicity than in those 
with low tumorigenicity. Overexpression of PROX1 in U-343 MG and suppression of 
PROX1 in U-343 MGa, increased and decreased cell proliferation and the cell cycle 
regulators cyclin A and E, respectively. In connection to this, SOX2 was shown as a positive 
regulator of PROX1. SOX2 and PROX1 were positively correlated in several gene 
expression datasets, including CCLE, HGCC and TCGA. SOX2 increased and decreased 
PROX1 expression upon overexpression and depletion modification of SOX2, respectively. 
CVT-313, a CDK1/2 inhibitor was found to decrease both SOX2 and PROX1 expression in 
the glioblastoma cells. 
Furthermore, we investigated the PROX1-related gene expression patterns, by a PROX1 
proxy signature, at single-cell level by using the single cell RNA-seq data from five 
glioblastomas. The PROX1 proxy signature was developed, since PROX1 measurement was 
not available in the single-cell dataset. We observed cell heterogeneity in each tumor 
regarding PROX1 proxy and its correlated genes. Among the top 100 PROX1 proxy 
correlated gene, 71% of them could be increased by PROX1 overexpression in U-343 MG.  
Finally, we investigated the interactome of PROX1. The transcription factor associated 
protein THRAP3 (also known as TR150) was detected in a PROX1 nuclear complex co-
immunoprecipitation mass-spectrometry analysis. THRAP3 was also lower expressed in 
grade IV gliomas than in grade II and III. Both THRAP3 and PROX1 localized to the nucleus 
of glioblastoma cells, and showed a positive correlation in TCGA samples. Furthermore, 
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THRAP3 was identified as a negative regulator of PROX1 by suppression of THRAP3 in U-
343 MGa. Since THRAP3 in other studies has been reported to bind and regulate SOX9, in 
this study we also found a positive correlation between SOX2, SOX9, PROX1, and THRAP3 
in TCGA glioblastoma cases. 
In conclusion, PROX1 could be a regulator of glioblastoma subtype gene expression 
signature. The reduction of PROX1 induced a mesenchymal transition in vitro and was 
correlated to shorter survival in TCGA glioblastoma cases. PROX1 expression showed 
heterogeneity in single cells within the tumor. Moreover, PROX1 levels could be increased 
upon overexpression of SOX2. PROX1 could interact with THRAP3, which has a 
suppressive effect on PROX1 levels. These findings provide novel insights into the 
mechanisms of intratumoral heterogeneity and transcription factor networks in glioblastoma. 
8.2.3 Paper III  
Identification of functionally distinct and interacting cancer cell subpopulations from a 
glioblastoma with intratumoral genetic heterogeneity 
Glioblastoma is a heterogeneous tumor with different cell populations within individual 
tumors. More knowledge on the interactions between these populations will be helpful for 
developing new therapeutic strategies and to provide further understanding of the 
fundamental tumor biology. In this study, we used the U-343 cell culture model to investigate 
more in depth differences between subpopulations of neoplastic cell populations within a 
single glioblastoma and model their communication with each other. The U-343 system 
consists of multiple established cell lines and the cell lines used here are denoted as U-
343MG, U-343MGa, U-343MGa 31L, and U-343MGa Cl2:6, which all originate from a 
single glioblastoma tumor. U-343MG and U-343MGa were originally derived from different 
parts of the tumor, and U-343 MGa 31L and U-343MGa Cl2:6 are subsequent derivatives 
from U-343 MGa. 
To establish the identity of the cells we first investigated the GFAP and FN1 expression 
patterns by immunofluorescence staining. U-343MG cells were GFAP-FN1+, whereas U-343 
MGa and its subclones were GFAP+FN1- cells. STR analysis validated with a high certainty 
level that the cell lines were derived from a single individual. Moreover, by using copy 
number analysis we identified common and specific genetic alterations in the four U-343 cell 
lines. These cell lines showed different proliferation rates and TMZ sensitivity. To further 
investigate the effect of intratumoral heterogeneity on drug sensitivity, we performed co-
culture experiments, mixing all four populations in equal amounts, and treated with or 
without TMZ for 5 and 10 days. U-343 MGa 31L was found as the least represented cell line 
when co-cultured with others, but during treatment with TMZ it became the most frequently 
occurring cell type in the co-culture. 
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To better understand if the U-343 model is representative of glioblastomas, we analyzed gene 
expression profiles from CCLE cell lines and single-cell sequencing data from individual 
glioblastomas, where U-343 MG and U-343 MGa cultures were shown to respectively 
resemble GFAP-FN1+ or GFAP+FN1- cell lines and individual cells within single 
glioblastomas as determined by single cell RNA-seq data analysis. Further analyses by 
generation and analysis of RNA-seq data in combination with invasion assays illustrated that 
U-343 MG had a more mesenchymal phenotype than others.  
Subsequently, we performed cell-to-cell contact and conditioned media experiments to study 
the interactions between clones. In cell-to-cell contact experiments, one GFP-labeled cell line 
was seeded relatively sparse on the top of another cell line. We especially found that U-343 
MGa Cl2:6 proliferated faster when growing on top of U-343 MG. Morphological 
observations and qPCR results from sorted GFP-labeled cells suggested a transition to a more 
mesenchymal gene expression based on increased expression of FN1 and SNAI2, and 
decreased levels of SOX2 and GFAP. To investigate the growth promoting mechanism 
affected by the cell-to-cell interaction, the involvement of NOTCH1 was tested, based on the 
notion of differential expression levels of NOTCH receptors and ligands obtained from RNA-
seq data and Westernblots. However, upon CRISPR-Cas9 knockout or shRNA- knockdown 
of NOTCH1 in U-343 MGa Cl2:6, its proliferation was further enhanced during co-culture 
with U-343 MG. As a second way of investigating interclonal communication, we focused on 
interactions between cells mediated by secreted proteins. Conditioned media from U-343 MG 
was found to have a growth inhibitory effect on U-343 MGa 31L. By generation and a 
combined analysis of mass spectrometry data of the cells secretome and RNA-seq data from 
the U-343 cells, TGFBI and ADAMTS1 were identified as highly expressed in U-343 MG, 
and therefore selected for further experiments by knock-down or use of recombinant protein 
to investigate their involvement in the co-culture proliferation phenotype of U-343 MG and 
U-343 MG 31L. 
In summary, this study illustrates that the cell populations within the individual 
heterogeneous tumor have common and specific properties. They communicate with each 
other by cell-to-cell contacts and by secreted proteins and this heterogeneity affect TMZ 
treatment results and recapitulate a tumor relapse phenotype. Thus, the U-343 model provides 
evidence for the complexity and importance of intratumoral heterogeneity in glioblastoma, 
and constitutes a suitable model system for inter-cellular signaling studies inside 
glioblastoma. 
 
 
 
 42 
8.2.4 Concluding graph 
 
 
Figure 8. Schematic diagram for the conclusions of this thesis. Upper figure shows that SFRP2 is secreted by mesenchymal 
subtype glioblastoma cells, and induces proneural to mesenchymal transition (PMT) of the non-mesenchymal cells by 
suppression of SOX2 and PROX1. In addition, the conditioned media from SFRP2-overexpressing cells increases CD206 
expression in macrophages. Lower figure shows the cell-to-cell interactions in the U-343 cell system by direct and indirect 
cells communication. U-343 MG increases the proliferation of U-343 MGa Cl2:6 via cell-to-cell contact, and it can also 
inhibit the proliferation of U-343 MGa 31L via secreted proteins.    
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8.3 DISCUSSION AND FUTURE PERSPECTIVES 
Glioblastoma is an aggressive disease with poor prognosis. Intratumoral heterogeneity is a 
characteristic hallmark that is thought to play an important role in glioblastoma progression. 
Better understanding of how heterogeneity appears and of the related consequences is thought 
to provide crucial biological insight to this devastating disease and provide ideas on novel 
treatment targets. In this thesis work, we set out to identify regulators of glioblastoma subtype 
gene expression states during tumor evolution (Paper I and II) and to investigate interclonal 
interactions in glioblastomas and relapse due to clonal variation in drug sensitivity (Paper III). 
8.3.1 SOX2 is a critical factor for the maintenance of a non-mesenchymal glioblastoma 
phenotype 
SOX2 is essential for embryonic stem cells and can be found expressed in neurogenic regions 
in human brain subventricular zone. In cancer, SOX2 has been reported as a key maintainer 
of the stem cell phenotype. The function of SOX2 in maintenance of non-mesenchymal 
glioblastoma phenotypes was also investigated with CMap analyses as shown in paper I. We 
performed hierarchical clustering using CCLE and HGCC publicly available dataset and 
identified major gene expression based subgroups. Subsequently transcription factors 
predicted to contribute to these differences in expression were analyzed by CMap, where 
SOX2 emerged as a key regulator. We also found SOX2 was higher expressed in 
glioblastoma tissue from non-mesenchymal subtype cases than in tissues from mesenchymal 
cases, which supported the experimental findings and the subtype regulatory role of SOX2 in 
glioblastoma. 
Herein, SFRP2 and PROX1 were identified as factors acting upstream and downstream of 
SOX2 respectively. SFRP2 is a secreted protein that has been described to act as an inhibitor 
of Wnt signaling and resulting in increased β-catenin phosphorylation and degradation. No 
publication has shown the connection between SFRP2 and SOX2. We initially found SFRP2, 
among several other genes, to be highly expressed in mesenchymal glioblastoma cell 
cultures, and subsequently it was found to have the capacity to decrease SOX2 expression, by 
using an overexpression screen. Furthermore, we found that a subset of TCGA glioblastoma 
cases with SFRP2high and SOX2low expression was enriched with mesenchymal subtype cases, 
supporting our finding that SFRP2 can induce a mesenchymal transition by suppression of 
SOX2 (Paper I). PROX1 is a transcription factor that was shown less expression on mRNA 
level in glioblastomas as compared to grade II and III gliomas. In paper II it was found as a 
downstream factor of SOX2 based on gene expression profiling. Published CHIP-seq data 
has described the PROX1 gene has a SOX2 binding site, thus supporting a direct 
transcriptional regulation. PROX1 was positively correlated and increased by SOX2. In 
addition, PROX1 was shown to bind with THRAP3, which also regulated GFAP level. 
According to the subtype information in TCGA database, both high SFRP2 samples and low 
PROX1 samples were found in glioblastoma mesenchymal subtype, suggesting the increase 
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of SFRP2 or decrease of PROX1 was related with mesenchymal transition. By RNA-seq 
analysis both overexpression of SFRP2 and suppression of PROX1, were shown to increase 
the support index for a mesenchymal gene signature. In a contrary manner, overexpression of 
SOX2 or PROX1 decreased the support index for a mesenchymal subtype signature (Paper I 
and II). 
The critical role of SOX2 as a regulator of glioblastoma subtype was confirmed in the cell-to-
cell contact model using the U-343 system (Paper III). U-343 cell line model system is 
composed of four different cell lines that originated from the same tumor. U-343 MGa Cl2:6 
is an astrocytic-like cell line, and it was switched to mesenchymal-like when growing on top 
of the mesenchymal cell line U-343 MG, in conjunction with the suppression of SOX2 
expression. These findings emphasize that loss of SOX2 is important for the mesenchymal 
transition. 
Mesenchymal transition has been reported in many situations in glioblastoma. Depletion of 
NF1 in proneural cells induces a mesenchymal subtype transition [79]. Recurrent 
glioblastomas are often of mesenchymal gene expression phenotype after treatment such as 
anti-angiogenic therapy [84]. Stimuli from the microenvironment, such as via hypoxia or 
residing immune cells, can also induce a mesenchymal subtype transition. There are several 
master regulators of the mesenchymal gene expression signature including STAT3, CEBPB, 
FOSL2, ZBTB18 (ZNF238), RUNX1, and TAZ [86]. In our studies we show that suppression 
of SOX2 or PROX1 induces a mesenchymal glioblastoma subtype transition. With respect to 
these factors, RNA-seq analysis reveals that overexpression of SOX2 decreased CEBPB, and 
overexpression of PROX1 decreased RUNX1, indicating that SOX2 and PROX1 may affect 
the expression of different mesenchymal regulators that are important during the transition, 
and may lay at different levels in the transcriptional regulation tree. PROX1 is proposed by us 
to be active downstream of SOX2, and both SOX2 and PROX1 are transcription factors that 
are essential for tissue development. Additional RNA-seq experiments should be performed 
to identify common and specific cell signaling pattern altered by SOX2 and PROX1 during 
the mesenchymal transition. 
Many factors have been shown involved in regulating stemness via SOX2 including 
pathways involving WNT/βcatenin, NOTCH, and Hippo. In paper I, we found that three type 
B genes, SFRP2, KLF4 and RGS5, were able to down-regulate SOX2 expression in an 
overexpression screen. Since SFRP2 is a secreted protein and thus may have the capacity to 
affect SOX2 levels in surrounding cells in a setting of intratumoral heterogeneity, we selected 
SFRP2 for further investigations. SFRP2 acted as a Wnt/β-catenin antagonist in our cells 
system since β-catenin levels decreased upon SFRP2 overexpression. However, the changes 
of β-catenin could not be directly connected with the decreased SOX2 levels, since 
suppression of β-catenin did not per se affect SOX2 levels. Thus the involvement of non-
canonical WNT-signaling pathway, including ROR2 and NFAT, will be investigated in 
continued studies. Furthermore, SFRP2 increased and decreased the expression of PDGFRB 
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and PDGFRA, respectively, which led us to investigate signaling downstream of the 
PDGFRs, including the AKT signaling pathway. AKT phosphorylation has previously been 
reported to regulate SOX2 in esophageal cancer [274]. In preliminary data (that will be 
included in later versions of paper I), overexpression of SFRP2 indeed decreased 
phosphorylation of AKT, and treatment with the AKT inhibitor MG2206 on U-2987 and U-
2997 suppressed SOX2 expression. This proposes a mechanism where SFRP2-AKT-SOX2 
constitutes a signaling axis in the case of mesenchymal transition induced by SFRP2. Further 
investigations are conducted with a focus on the mechanisms by which SFRP2 may regulate 
AKT activity. 
KLF4 is one of the four Yamanaka factors that together with SOX2, OCT4 and c-MYC are 
able to reprogram cells to iPS cells [73]. Notably in paper I, KLF4 that was part of the 
previously identified type B genes, was here found in the overexpression screen to be able to 
suppress SOX2. Furthermore, SFRP2 was found to have the capacity to increase the 
expression of KLF4. This suggests that KLF4 may act as an intermediate factor between 
SFRP2 and SOX2. According to the data from publicly available TCGA glioblastoma cases, 
KLF4 is positively and negatively correlated with SFRP2 and SOX2, respectively. These 
findings pose the question of how the Yamanaka factors cooperate during cell 
reprogramming, and in the situation of normal development: if KLF4 actually has an 
inhibitory effect on SOX2 during normal development. The Yamanaka factors are most often 
studied during overexpression, which overrides normal gene regulatory effects. Besides, how 
KLF4 suppresses SOX2 is another question we need to answer: does KFL4 bind directly to 
the SOX2 promoter? In our preliminary data, we found that KLF4 overexpression decreases 
AKT phosphorylation, as similar to SFRP2. The possibility that KLF4 binds directly to the 
SOX2 gene and suppresses its transcription is being investigated by ChIP. 
RGS5, regulator of G protein signaling 5, belongs to the GTPase activator family. RGS5 has 
been studied in vascular biology where it influences the angiogenesis during tumor 
progression, and furthermore has been used as a marker for pericytes. In paper I, RGS5 was 
found together with SFRP2 and KLF4 to be able to downregulate SOX2 expression. In the 
TCGA database, we found RGS5 to be negatively correlated with SOX2 in the classical 
subtype but not in the proneural and mesenchymal glioblastoma subtypes. Additional studies 
on RGS5 in glioblastoma would be of interest. 
Mesenchymal transition was found in this thesis work to be induced either by proteins 
secreted from mesenchymal cells including SFRP2 in paper I, or by cell-to-cell interactions 
with mesenchymal cells, such as during the direct cells contact between U-343 MGa Cl2:6 
and U-343 MG in paper III. These, and other findings suggest that initially non-mesenchymal 
cells transition to a mesenchymal state induced by certain signals. What the underlying 
trigger of these signals is remain to be better understood. It may be genetic in the case of loss 
of NF1. But since NF1 is not lost in all mesenchymal subtype cells, it must also be due to 
other stimuli, potentially microenvironmental ques triggered by hypoxia, inflammation tumor 
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state, wound healing effects, or certain secreted factors or cell-to-cell contacts where non-
mesenchymal glioblastoma cells are induced to transition to a mesenchymal subtype by other 
cells. These alterative reasons are consistent with the previous reports that mesenchymal 
subtype occurs at a later stage during tumor evolution. 
8.3.2 The effect of heterogeneity on glioblastoma cell proliferation and cell cycle 
Another important finding in this thesis work is the connection between glioblastoma subtype 
transitions and the change of proliferation rate and levels of cell cycle related proteins. In 
paper I and II, overexpression of SFRP2 or suppression of PROX1 decreased cell 
proliferation and expression of cyclins, such as Cyclin E. Recently it was reported that 
phosphorylation of SOX2 by a Cyclin E- and CDK2-complex lead to stabilization of SOX2. 
Thereby, treatment with CVT-313, an inhibitor of CDK1/2 kinase activity, leads to 
destabilization and degradation of SOX2 [199]. In our work (Paper II), CVT-313 treatment, 
or SOX2 suppression, both also led to decreased PROX1 levels. Thus, this connects 
glioblastoma subtype regulation and cell cycle. Though it still remains to study if direct 
modulation of cell cycle components, including cyclin E, can induce a subtype transition. In 
connection to this, others have reported that cell cycle was extended during differentiation of 
neural precursors and neurogenesis by increased expression of anti-proliferative genes, such 
as CDKN2A (p16INK4A), CDKN2D (p19ARF), and CDKN1A (p21Cip1). Bmi1, a member of 
polycomb group (PcG) proteins which mediates suppression of Ink4a/ARF cell cycle 
inhibitory proteins, p16 and p19, has been shown essential for self-renewal of neural 
precursors [275]. This suggests that the mesenchymal subtype cells represent in fact more 
differentiated and proliferate less as compared to non-mesenchymal subtype cells. 
The changes in cell proliferation point to a connection with metabolism. It has been shown 
that in cellular reprogramming to iPSCs requires a shift from oxidative phosphorylation 
(OXPHOS) to glycolysis to produce more lactate, which is insensitive to O2 levels [276]. In 
connection to this, nothing is really known about metabolic differences between glioblastoma 
subtype cells. In preliminary studies (data not included in thesis) we have found that SOX2 
overexpression changes the mitochondrial morphology and decreases the OXPHOS, 
suggesting that the proneural subtype is more prone to glycolysis than mesenchymal subtype. 
Thus, in a tumor progression setting from non-mesenchymal to more mesenchymal subtype 
glioblastoma cells, cells would be predicted to shift to OXPHOS. Interestingly, PROX1 has 
also been shown to regulate the gene expression of metabolic clock genes, and the perturbed 
clock is linked to glioma [255]. Further research on energy metabolism, and metabolic clock 
control, with the events of subtype transition should be considered. 
Several pathways have been shown to regulate the cell cycle in neural precursors including 
Notch, Wnt, PDGF, Fibroblast growth factor (FGF) and Sonic hedgehog (SHH) signaling 
[277]. Notch1 binds with its ligand Jagged 1 and promotes proliferation of neural precursors 
[278]. Wnt signaling can upregulate cyclinD1 and shorten cell cycle in neural precursors 
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[279]. SHH binds with Ptc receptor and upregulates Gli and Bmi1 to promote neural 
precursors proliferation [280]. Interestingly, Notch regulator Numb has also been reported to 
suppress SHH signaling by targeting Gli [281]. FGF and their receptors, such as FGF2, 
FGF15, and FGF receptor 2 have also been shown to shorten cell cycle and increase 
proliferation [282]. In paper III, cell-to-cell interaction was shown to affect cell proliferation, 
where U-343 MGa Cl2:6 proliferated faster when growing on top of U-343 MG. However, 
NOTCH1 had an inhibitory effect since CRISR-Cas9 knockout or shRNA suppression of 
NOTCH1 enhanced proliferation. This raises the question of the proliferation regulatory role 
of NOTCH1 in glioblastomas in a setting with intratumoral heterogeneity. Further studies 
also need be conducted to identify the proliferation-promoting factors that were masked by 
NOTCH1. 
Further, the cell communication mediated by secreted factors was also found in the U-343 
system, where a large number of secreted proteins were identified by secretome analysis, as 
examples, TGFBI and ADAMTS1 were tested and acted as suppressors on the proliferation 
of U-343 MGa 31L and secreted by U-343 MG. Further secreted factors were identified but 
not tested since the effect on proliferation by secreted factors in the U-343 model system 
appeared less potent than the cell-to-cell contact effect. It should also be noted that the cell-
to-cell effects might be context dependent. Therefore it is suggested that interaction effects 
are also assessed in other models systems, as for example in neurosphere growth conditions 
and in vivo by mouse or zebrafish models. Our efforts can thus be seen to have defined 
models that now can be tested in these other systems. Also the SPECS method was found to 
be very powerful to identify secreted proteins without interference from the serum, and may 
be suitable to apply and develop for other models and systems. The correlation analysis 
between proteomics data and RNA-seq data provides a useable method for identification of 
relevant proteins. 
8.3.3 The interaction with the tumor microenvironment  
In paper I, we performed gene expression analysis of macrophage, pericyte and vascular 
markers in TCGA samples and noticed elevated expression of these in cases with a 
SFRP2highSOX2low expression pattern, and in which most of the cases belonged to 
mesenchymal subtype. Moreover, spatial gene expression analysis indicated a SFRP2 
signature in vascular tumor areas, whereas a SOX2 signature presents more cellular areas. 
This suggests that mesenchymal tumor cells in vascular areas may attract immune cells. This 
is consistent with previous reports where M2 macrophages were found enriched in 
mesenchymal subtype glioblastomas [41]. By the addition of conditioned media from cells 
with SFRP2 overexpression as compared to the native cells, CD206 expression was higher 
induced on human macrophages, suggesting a M2 polarization. However, further studies 
need to be conducted to identify the relevance and mechanism by which SFRP2 induced this 
effect, direct effect on the macrophages, or via a secondary secreted factors from the tumor 
cells as for example CXCL12. CXCL12 was higher expressed in the tumor cells upon SFRP2 
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overexpression. The CXCL12-CXCR4 axis has previously been shown to be important for 
immune cell recruitment in glioblastoma [283]. 
The reason for why non-mesenchymal and mesenchymal subtype glioblastoma cells have 
different spatial distribution is not well studied. In this thesis, we noticed that the 
mesenchymal cells have stronger invasive capacity and mesenchymal genes expression based 
on in vitro Matrigel invasion assay and RNA-seq data. We also showed overexpression of 
SFRP2 and SOX2 respectively increased and decreased cell invasion (paper I). It could be 
vessel components/cells/microenvironment that shift the cancer cells to get mesenchymal 
features. However, we did not show evidence if this mesenchymal transition is plastic and 
reversible. Further experiments will be performed to see if mesenchymal cell state induced by 
SFRP2 could change back to original non-mesenchymal state after removal of SFRP2. 
8.3.4 The effect of intratumoral heterogeneity on drug resistance in glioblastoma 
In general, there is no single phenotype that can explain appearance of drug resistance. It is 
context dependent with regard to what drug you mean. In general, cytostatic drugs, which 
TMZ belongs to, are drugs that have an antiproliferative effect and preferentially kills 
dividing cells. The mechanism that allows cells to initially display or develop resistance to 
this type of drug may be very different as compared towards more novel targeted therapies, as 
for example EGFR inhibitors. In a perspective of intratumoral heterogeneity theoretically the 
main affecter is the heterogeneity in itself, with populations of cells with distinctly different 
phenotypes, which may range from differences in differentiation markers to mutations in 
different cancer driver genes. The heterogeneity may also present itself in more abstract 
phenotypes as for example drug sensitivity, with respect to still not yet known confounders. 
Here, the effect of heterogeneity on TMZ response was modeled in our U-343 system that 
pose as a suitable system to model appearance of drug resistance in glioblastoma. Still, given 
the extensive heterogeneity is also found between individual glioblastoma cases, further 
similar cell models needs to be generated and studied to get a representative repertoire of 
glioblastoma subgroups. In paper III, we analyzed cell ratios of each U-343 cell line when 
grown in mixture with the other U-343 cells with or without the presence of TMZ. Clearly, 
different cell lines have distinct inherent sensitivities to TMZ treatment. One cell line 
decreased to a small percentage of the whole co-cultures and would thus be difficult to detect 
in a corresponding initial tumor, however upon TMZ treatment it continues to proliferate and 
becomes the dominant population and thus could represent a cell population that cause tumor 
relapse after treatment. It is also striking how short time is needed to observe a clonal 
selection. The U-343 cells lines are relatively easy to culture with robust proliferation rate. 
Still, after only 10 days of culturing, the cells constitute only 1% of the cell populations. This 
model highlights a potential mechanism of treatment failure and appearance of a resistant 
drug population. To overcome this, in the case of drugs that resistance will be developed 
against, it is suggested to investigate combinatorial treatment approaches. 
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In summary, this thesis investigates causes and effects of intratumoral heterogeneity in 
glioblastoma during tumor evolution and progression. That is, non-mesenchymal cells in 
vascular areas are affected by SFRP2 that leads to a cascade of increased KLF4 levels, 
decreased AKT-phosphorylation, SOX2 and PROX1 levels, and decreased cell cycle proteins 
and proliferation, as well as transition to a mesenchymal gene expression signature. Within 
the tumor, the non-mesenchymal and mesenchymal cells may affect each other’s growth, 
invasion, subtype states and drug sensitivity, resulting in treatment failure where the less 
sensitive population has taken over in the relapsed tumor. Therefore, we suggest that drugs 
that inhibit mesenchymal transition in combination with anti-proliferative drugs should be 
investigated as novel treatment strategies. 
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